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Abstract 
  
 Cardiovascular disease is the leading cause of death and disability worldwide. Oxidative 
stress has been implicated in many types of cardiovascular disease. Chronic cardiac stress 
conditions have been shown to be associated with an increase in myocardial oxidative stress 
following myocardial infarction, which in turn may lead to depressed contractile function, 
myocardial remodeling and heart failure. Antioxidants play a protective role against oxidative 
stress damage through the removal of free radical intermediates and inhibition of oxidation 
reactions. An imbalance of free radicals and antioxidants results in cellular and sub-cellular 
damage. Therefore, treatment with non-enzymatic antioxidants may provide protection against 
high levels of free radicals. We investigated, in three different studies, if treatment with 
antioxidants can protect the heart under conditions of oxidative stress. In the first study, a 
complex dietary supplement composed of numerous antioxidants and anti-inflammatory 
components was given to C57BL/6 mice that received a whole body radiation dose of 5 Gy to 
investigate potential cardioprotective effects by measuring cardiac antioxidant status and 
apoptosis. In the second study, the same complex dietary supplement was given to Thy1-GFP 
mice that received a radiation dose of 10 Gy to the head to investigate the abscopal effect on the 
heart by measuring cardiac inflammation and fibrosis. In the final study, the potential 
cardioprotective effects of secoisolariciresinol diglucoside, a compound found in flaxseed, was 
investigated in a Wistar rat model of pulmonary arterial hypertension by correlating cardiac 
functions with oxidative stress. We have shown that treatment with antioxidants may offer some 
protection to the heart in these models of oxidative stress though it is important to consider the 
extent of oxidative stress and when developing a antioxidant treatment protocol.  
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Cardiac Remodeling and Failure 
  
 The heart pumps blood that carries oxygen and nutrients to all parts of the body. The 
heart muscle receives its own blood supply from a system of coronary arteries. Adequate blood 
supply is crucial for normal function of the heart [1]. The left and right side of the heart are 
anatomically and electrically connected resulting in identical contraction rates between the 
chambers. In the case of an abnormality of one pump it is essential to take into account the 
effects of the other pump [2]. Impaired blood flow can occur because of cardiovascular disease 
(CVD). CVD is responsible for over 17.3 million deaths per year, and is the leading cause of 
death and disability worldwide [1; 3]. Types of CVDs include those due to atherosclerosis, such 
as: ischemic heart disease, stroke, and diseases of the aorta and arteries; or those due to other 
causes such as cardiomyopathy [1].  
   
 Atherosclerosis is the major source of morbidity and mortality in the developed world 
and claims more lives than all types of cancer combined [4]. It is characterized as a thickening of 
the arterial wall caused by the accumulation of cholesterol deposits in macrophages. This 
thickening forms an atherosclerotic plaque, which narrows the lumen of the artery, reducing 
blood flow. Progressive narrowing and reduced blood flow to the point that metabolic needs of 
the heart are no longer met will cause ischemia [5]. Atherosclerotic plaques can abruptly rupture, 
causing a blood clot, compromising oxygen supply to target organs even further [4; 5]. Blockage 
in the coronary artery leads to ischemic death of cardiomyocytes and eventually myocardial 
infarction. Restoring blood flow is crucial, but reperfusion can lead to further damage to 
endothelial cells and cardiomyocytes [6]. After ischemic insult to the myocardium the 
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inflammatory repair response is activated. Stressed myocardial cells release cytokines which 
leads to microembolism, platelet activation, neutrophil plugging, and endothelial cell dysfunction 
further reducing blood flow and increasing myocyte damage and death [6; 7]. To compensate 
with the loss of myocytes, hypertrophy is activated in the remaining viable cells. There are two 
different hypertrophic phenotypes depending on how the shape of the myocyte is changed. 
Concentric hypertrophy, due to pressure overload, is characterized by parallel addition of 
sarcomeres and increase in diameter of cardiomyocytes, resulting in wall thickening. Eccentric 
hypertrophy, due to volume overload or prior infarction, is characterized by addition of 
sarcomeres in series and lengthening of cardiomyocytes. This results in thinning of the wall and 
ventricular dilation [8-10]. Atherosclerosis is not the only cause of hypertrophy in CVD. 
Hypertrophic cardiomyopathy, specifically hypertrophy of the myocardium, is the most common 
form of monogenically inherited heart disease [11]. Prolonged hypertrophy can lead to 
myocardial scarring, where fibrotic tissue replaces normal tissue lost by damage [10]. Cardiac 
fibroblasts account for up to two-thirds of all heart cells and are regulators of extracellular matrix 
(ECM) remodeling [12; 13]. In myocardial infarction the infarct area is infiltrated by modified 
fibroblasts called myofibroblasts. Myofibroblasts form granulation tissue used to clear dead 
cells, breakdown ECM and stimulate angiogenesis to re-vascularize the ischemic tissue. 
Prolonged myocardial infarction causes myofibroblasts to increase synthesis of structural ECM 
proteins which leads to scar formation. This scar formation is essential to repair where 
cardiomyocytes were lost due to damage in order to prevent rupture of the myocardial wall, but 
excessive accumulation results in fibrosis. Fibrosis stiffens the myocardium and hampers the 
diastolic filling [12]. Prolonged ischemia, hypertrophy and fibrosis, where the heart is unable to 
pump sufficiently and maintain proper blood flow, will eventually lead to heart failure. 
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 The pathophysiological processes of heart failure are highly complex and unfortunately 
current therapy is based on a regimen of drugs that only target symptoms [2]. The most common 
drugs used for the treatment of heart failure are angiotensin-converting enzyme (ACE) inhibitors 
and β-blockers, which aim to delay or even reverse the maladaptive remodeling process [8]. ACE 
inhibitors work by reducing the production of angiotensin II and increasing bradykinin 
production, which results in a drop of blood pressure, while β-blockers reduce heart rate. Both 
can be used together to improve symptoms associated with heart failure [14]. While these drugs 
can be effective they may cause adverse side effects and are not suitable for all patients. 
Diagnosis of heart failure can be quite difficult as most symptoms are non-specific and can be 
interpreted as other problems [14]. Heart failure can be defined as acute heart failure and chronic 
heart failure. Acute heart failure is due to a fall in left ventricular stroke volume which can lead 
to hypotension or cardiogenic shock [2; 15]. Chronic heart failure is due to prolonged ventricular 
remodeling or dilatation [2]. Dilation and subsequent thinning of the ventricular wall results in 
increased diastolic and systolic wall stress in the right and left ventricular chambers. Cardiac 
contractility and relaxation will decrease as chamber dilation continues, leading to heart failure 
[16]. While heart failure is complex, all of the processes that lead to heart failure (ischemia, 
hypertrophy, remodeling etc.) appear to involve oxidative stress. Therefore, a better 
understanding of the oxidative stress mechanism may enable the development of novel and 
effective therapeutic strategies against heart disease.    
 
Oxidative Stress 
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 Oxidative stress occurs when there is an increase in free radicals, resulting in an 
imbalance between antioxidants and reactive oxygen species (ROS). Excess free radicals can 
damage DNA, cell membranes, proteins and other macromolecules [17]. Free radicals are 
formed when a molecule contains one or more unpaired electron(s) in the outermost orbital, 
making the molecule highly reactive [18; 19]. Due to its unique diradical configuration, oxygen 
is a major source of free radicals [18]. Types of ROS include free radicals such as superoxide 
anion (O2˚-) and hydroxyl radical (•OH), and compounds that are not free radicals per se, such as 
hydrogen peroxide (H2O2) [20]. ROS are generated by the mitochondrial electron-transport 
chain, the major source of ROS in the heart, and oxygen-metabolizing enzymatic reactions such 
as xanthine oxidase, uncoupled nitric oxide synthases and NADPH oxidases [17; 21]. 
Mitochondria provide energy in the form of adenosine triphosphate (ATP) to the cell. Electrons 
flow along the respiratory transport chain through a series of electron transport carriers located 
on the inner mitochondrial membrane called complexes I, II, III and IV. Normally, only 1% to 
2% of electrons leak out and form O2•- which is scavenged by manganese superoxide dismutase 
(Mn-SOD). Typically, ROS act as signaling molecules that regulate numerous cellular processes 
[21]. ROS are also important for immune defense, in particular for oxidative burst reaction which 
is essential for phagocytosis [17; 22]. However, under pathophysiologic conditions, the electron 
transport chain may become uncoupled and lead to increased O2•- production [20]. Leaked O2•- 
converts ferric iron to ferrous iron in the Haber-Weiss reaction. Ferrous iron reacts with H2O2 in 
the Fenton reaction generating highly reactive •OH, which can cause significant damage [21]. 
High amount of ROS are implicated in many pathological diseases. In fact, numerous studies 
strongly suggest a role for ROS in cardiovascular pathophysiology. ROS have been implicated in 
the progression of atherosclerosis [4]. Increased levels of ROS observed following myocardial 
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infarction is shown to be directly involved in the development of contractile dysfunction through 
modification of proteins important for excitation-contraction coupling [20; 23]. ROS has also 
been shown to be involved in the development of cardiac hypertrophy by activating hypertrophy 
signaling kinases and transcription factors as well as remodeling proteins [20; 22; 23].  
 
Oxidative Stress Mediated Damage 
 
 The adverse effects of oxidative stress is mainly due to DNA damage. •OH can react with 
DNA by addition to double bonds of DNA bases and also by removing a hydrogen atom from 
the methyl group of thymine and the carbon-hydrogen bonds of 2'-deoxyribose [24; 25]. 
Hydrogen abstraction in the 2'-deoxyribose of DNA due to •OH causes double stranded breaks 
[24]. All of the bases can be modified by ROS but guanine is highly susceptible, where ROS 
causes the oxidation of deoxyguanosine to 8-hydroxyguanine (8-oxodG). If unrepaired this 
results in 8-oxodG mispairing with deoxyadenosine rather than deoxycytosine resulting in a 
cytosine–adenine point mutation [26]. 8-oxodG has been implicated in many pathological 
conditions such as various types of cancer, diabetes and cardiovascular disease [24]. •OH can 
also cause the modification of cytosine to 5-methylcytosine which results in the generation of 
thymine. Since thymine is a normal component of DNA the new thymine-guanine base pair may 
avoid detection by repair mechanisms, creating a point mutation [26]. Cells respond to DNA 
damage by activating cell cycle checkpoints to provide time for DNA repair machinery to mend 
the damage, but these processes are imperfect. In fact, exposure of cells to H2O2 may suppress 
DNA repair as well as inducing damage [24; 26; 27]. Excess ROS will also lead to oxidative 
degradation of lipids in a process known as lipid peroxidation. Free radicals initiate lipid 
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peroxidation by attacking double bonds associated with polyunsaturated fatty acid (PUFA), 
resulting in the removal of a hydrogen atom from a methylene group. PUFA peroxyl radicals can 
abstract hydrogen atoms from adjacent PUFA, forming an hydroperoxide and another lipid 
radical, creating a chain reaction [28]. When prolonged oxidative stress damages cells beyond 
repair the cell may activate mechanisms to initiate cell death. 
  
 Cardiomyocyte cell death is known to contribute to the development of heart failure. 
There are three forms of cell death that occur in the heart; necrosis, apoptosis, and autophagy. 
Necrosis is a disruption of cell membrane resulting in the release of intracellular contents [29]. 
Apoptosis is tightly regulated/programmed cell death that is essential to organ development, 
control of cell number and deletion of harmful/abnormal cells. Prolonged increase in apoptosis 
has been shown to play a major role in the development of various cardiovascular disorders and 
heart failure [29; 30]. Apoptosis exists as two pathways; the intrinsic pathway and the extrinsic 
pathway. The intrinsic pathway is activated by biological, chemical, and physical stimuli that 
send signals to the mitochondria and endoplasmic reticulum [31]. The first step is the activation 
of pro-apoptotic proteins in the cytoplasm, including B-cell lymphoma (Bcl)-2-associated X 
protein (Bax). Pro-apoptotic Bax can open mitochondrial channels releasing cytochrome c. Anti-
apoptotic Bcl-2 can prevent the release of cytochrome c by binding to Bax, thus preventing the 
opening of mitochondrial channels. Once released cytochrome c will bind to apoptotic protease 
activating factor (Apaf)-1, causing a conformational change of the protein. The Cytochrome 
c/Apaf-1 complex then activates caspase-9, creating an apoptosome. The apoptosome cleaves 
and activates caspase-3 and -7. These activated caspases then translocate to the nucleus and 
cleave DNA repairing enzymes and activate endonucleases which cleave DNA, resulting in 
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apoptosis [29-31]. The extrinsic pathway involves cell surface death receptors and is activated 
when a death ligand binds to its receptor. This results in the formation of the death-inducing 
signaling complex which activates caspase-8. Caspase-8 has two roles: it can cleave and activate 
caspase-3, resulting in apoptosis, or can lead to the release of cytochrome c by the mitochondria, 
causing intrinsic apoptosis [31]. Apoptotis is characterized by cell shrinkage, plasma membrane 
blebbing, chromatin condensation, DNA fragmentation and finally, fragmentation of the 
cytoplasm and nucleus into membrane-enclosed apoptotic bodies that undergo phagocytosis [31; 
32]. Increased apoptosis has been shown to be involved in many cardiovascular diseases 
including atherosclerosis, myocardial ischemia/reperfusion injury, diabetic cardiomyopathy, and 
chronic heart failure [29; 33-35]. Oxidative stress induced cardiomyocyte death is associated 
with the structural and biochemical changes indicative of apoptosis [30]. Previous studies have 
shown that cardiomyocyte apoptosis in atherosclerosis, myocardial infarction, 
ischemia/reperfusion injury, cardiomyopathy, and heart failure is triggered by oxidative stress 
[30; 36; 37]. It is clear that oxidative stress induced apoptosis is involved in cardiovascular 
disease. 
 
Autophagy 
 
 While the role of apoptosis in cardiovascular disease is well established the role of 
autophagy is not completely clear. Autophagy is a catabolic pathway for bulk turnover, or 
recycling, of long-lived proteins and organelles via lysosomal degradation and is induced by 
signals due to various stressors, such as starvation, metabolic stress, high glucose and hypoxia. 
There are three types of autophagy: chaperone-mediated autophagy, microautophagy and 
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macroautophagy. Chaperone-mediated autophagy requires the complete unfolding of the 
autophagic materials prior to entry into lysosomes. It is initiated by recognition by a hsc70-
containing complex. Once bound, protein substrates then translocate into the lysosomal lumen, 
resulting in unfolding and degradation. This process allows for individual proteins to be singled 
out [38; 39]. Microautophagy is when lysosomes directly engulf small pieces of the cytoplasm 
through inward invagination of the lysosomal membrane [38; 40]. Macroautophagy is the most 
studied of the three and is characterized by the formation of a double-membrane vesicle called 
the autophagosome. Autophagosome formation involves autophagy-related proteins (ATG), 
which are downstream of mammalian target of rapamycin (mTOR). In stress response mTOR is 
inhibited allowing the activation of the unc-51-like kinase (ULK1) complex 
(ULK1/Atg7/Atg13). This stimulates phagophore formation, and activates the beclin-1 complex 
which promotes phagophore nucleation and elongation. Membrane elongation involves the 
ATG12-ATG5 complex and microtubule-associated protein 1 light chain 3 (LC3). LC3-I is 
normally located in the cytosol until it is conjugated by ubiquitin-conjugating enzyme-like 
molecules ATG7 and ATG3 to LC3-II. LC3-II is then localized to the autophagosome membrane 
with the assistance of ATG5. LC3-II remains on the autophagosomes until lysosomes are fused 
to the autophagosomes to generate autolysosomes. The contents inside the autolysosomes are 
lysed and degraded and the products are released into the cytosol and used in metabolic 
pathways [38; 39]. Oxidative stress has been reported to serve as important stimuli of autophagy 
during periods of stress. Increased ROS degrades inhibitors of beclin-1, allowing for beclin-1 
activation and increased autophagy in the cell [39]. Autophagy in the heart is used to maintain 
homeostasis and is an important survival mechanism when cells need to recycle amino and fatty 
acids during starvation [29]. A defect in the autophagic pathway can lead to ventricular 
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dysfunction and heat failure [41]. Autophagy may also be detrimental and lead to excessive self-
digestion and degradation of essential cellular components. Autophagy is upregulated in 
response to ischemia and is thought to promote survival by maintaining energy homeostasis. 
During ischemia, oxygen and nutrient supplies are decreased causing inactivation of mTOR, 
leading to autophagy for cell survival [42]. During reperfusion though, beclin 1 is markedly 
upregulated due to an increase of ROS from reoxygenation after ischemia. This leads to 
excessive activation of autophagy that could cause cell death [38; 42]. Autophagy is also 
involved in heart failure, but whether autophagy serves a protective or a deleterious role is not 
clear. Autophagy may be an adaptive response to heart failure by increasing protein degradation 
and decreasing cardiac hypertrophy. Though, excessive autophagy in load-induced heart failure 
leads to cell death, loss of cardiomyocytes, and may contribute to the worsening of heart failure 
[31; 38; 42]. Therefore, further research is needed to fully understand the role of autophagy in 
cardiovascular health. 
  
Antioxidant Potential 
 
 To maintain homeostasis the cell contains antioxidants that scavenge ROS. An 
antioxidant is a molecule capable of inhibiting the oxidation of other molecules by being 
oxidized themselves, so antioxidants are often reducing agents. Antioxidants remove free radical 
intermediates and inhibit other oxidation reactions, providing protection against oxidative stress 
induced damage. Both enzymatic and non-enzymatic antioxidants offer protection against ROS 
[18]. Three of the most important enzymatic antioxidants are SOD, glutathione peroxidase (GPx) 
and catalase [43]. SOD catalyzes the dismutation of O2•- to H2O2 and O2. Mn-SOD is the primary 
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defense against mitochondrially generated ROS as it is located inside the mitochondria [21; 43]. 
Catalase is found in the cytoplasm and catalyzes the reduction of H2O2 to H2O [43]. Glutathione 
is also located in the cytoplasm of the cell. Reduced glutathione (GSH) can convert H2O2 to H2O 
but requires GPx as a catalyst. This reaction will convert glutathione to its oxidized state 
(GSSG). Glutathione reductase (GSR) can convert GSSG back to GSH by using NADPH as an 
electron donor. This allows GSH to act as an antioxidant again [18; 43; 44]. Many studies have 
investigated these antioxidants in cardiovascular disease. SOD, GPx and catalase levels have 
been shown to decrease in animal models of heart failure [45]. In heart muscle GSH depletion 
and accumulation of GSSG can occur within minutes of initiating oxidative stress [44; 46]. Many 
studies have also shown that increasing these antioxidants can improve cardiovascular health in 
models of disease [43]. Several studies have shown increased SOD offers protection against 
ischemia-reperfusion injury [18; 47-49]. SOD and catalase have been shown to cause reduction 
in infarct size in dogs that underwent 90 min of coronary occlusion and 24 h of reperfusion  [43; 
48]. The therapeutic role of various non enzymatic antioxidants, such as vitamin E, has been 
greatly studied. Treatment with vitamin E in guinea pigs increased GSH/GSSG ratio, decreased 
lipid peroxides, decreased oxidative stress and  attenuated heart failure [45; 50]. Also, studies 
with vitamin A, C and E in a rat model of ischemia/reperfusion reported that redox ratio was 
increased and lipid peroxidation was decreased [18; 51; 52]. Vitamin A, C and E also decreased 
lipid peroxides and improved cardiac function in myocardial infarction patients [18]. It is clear 
the antioxidants may have a therapeutic role in oxidative stress induced cardiovascular disease. 
 
 The main objective of this study was to use different models of oxidative stress in order 
to study the molecular effects and mechanistic response of the heart. Also, if/how different 
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models of oxidative stress lead to different or similar cellular responses. Furthermore, the role of 
various antioxidants was also studied. Since many cardiovascular diseases are due to oxidative 
stress where high levels of free radicals overwhelm the enzymatic antioxidant line of defense, 
supplementation with non-enzymatic antioxidants may provide a promising treatment option. 
Both a mouse and rat model was used to measure different parameters of oxidative stress 
response and cardiac remodeling, such as, cell death, antioxidant levels/activity, inflammation, 
fibrosis and cardiac function and any possible protective effects of antioxidant supplementation. 
The three different studies investigated oxidative stress over a broad timeline; 21 days-120 days 
after oxidative stress inducing treatment. This allowed the visualization of the response of the 
heart to oxidative stress at different time points and how it differs. Also, all three studies 
investigated pre-treatment with antioxidants versus co-treatment/post-treatment and how pre-
treatment may be a better antioxidant treatment option. These studies aim to further our 
understanding of cardiac oxidative stress and potential benefits of antioxidant supplementation. 
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Chapter 2 - Impact of a Complex Dietary 
Supplement on Radiation-Induced Cardiac 
Damage 
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Abstract 
  
 A high dose of whole body radiation has been shown to lead to oxidative stress and 
cardiovascular disease. Studies have recently shown that a complex dietary supplement 
consisting of anti-oxidants and anti-inflammatory compounds can increase longevity, decrease 
markers of ageing and impart protection against radiation induced oxidative stress and 
inflammation in irradiated mice. Although autophagy is induced in response to oxidative stress 
its role in radiation induced cardiac damage has not been investigated. We tested the hypothesis 
that a complex dietary supplement can attenuate cardiac oxidative stress and apoptosis in mice 
exposed to a high dose of ionizing radiation. C57BL/6J male mice were fed a complex dietary 
supplement before (30 days) and after (48 hours, 30 days or 120 days) a whole body 5 Gy dose 
of radiation or just after (48 hours, 30 days or 120 days) the radiation exposure. Hearts were 
collected and the protein levels of antioxidants Mn-SOD and catalase, apoptosis markers caspase 
3, Bax and Bcl2 and autophagy marker LC3b I and II were examined. Protein levels of both Mn-
SOD and catalase increased 48 hours after irradiation in both supplement fed groups but did not 
change after 30 or 120 days when compared to time matched 5 Gy radiation treatment alone. 
Pro-caspase 3 and Bax:Bcl2 ratio decreased in both supplement fed groups 48 hours after 
treatment when compared to time matched 5 Gy radiation treatment alone. 30 and 120 days after 
treatment pro-caspase 3 decreased only when supplement was fed after irradiation. LC3bII:I ratio 
increased only at 48 hours after treatment in both supplement fed groups when compared to 5 Gy 
radiation treatment alone. Our results suggest that a dietary supplement design to offset the 
effects of oxidative stress may provide some protection to the heart against a high whole body 
dose of radiation. 
15 
 
Introduction 
 
 Ionizing radiation (IR) is an electromagnetic wave or particle that can remove an electron 
from an atom or molecule, leading to the formation of chemically reactive ions. Types of IR 
include α particles, β particles and γ rays. α and β particles have a high ionizing power but a low 
penetrating power. Photons of relatively low energy are able to interact with electrons of organic 
molecules to generate 'excited' states where the energy levels of the molecular orbitals are raised. 
In the case of γ rays, when the photon energies are high, the electronic excitation is sufficient for 
electrons to be ejected from their orbital, resulting in molecular ionization [53]. The absorption 
of IR in living cells can directly disrupt atomic structures, producing chemical and biological 
changes. The absorbed dose measures the energy absorbed in a specified region and depends on 
the particular material or tissue placed in an X-ray beam [54]. The basic unit of measurement of 
absorbed dose is gray (Gy), which is 1 joule of initial energy per kilogram of tissue. An effective 
dose, called sievert (Sv), is obtained by adding the dose equivalent to each organ modified by 
each organ’s radiosensitivity [54]. The damaging effects caused by IR are due to the geometry of 
the physical energy deposition per unit track length (per μm) of the impacting radiation, referred 
to as linear energy transfer (LET) effects [26; 55]. The density of ionization events is higher for 
radiation with heavy ions than for photons and protons. Heavy ions deposit a large amount of 
energy in a small distance, while low LET radiation, such as γ rays, will deposit energy 
infrequently along its track [56; 57]. LET determines the relative potency of different types of 
radiation in causing biological effects. Following exposure to high LET radiations the yield of 
damaged sites in DNA is greatly increased [26; 58-62]. 
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 IR can damage cells by various mechanisms including DNA damage [63]. IR induced 
DNA damage includes double strand breaks, single strand breaks and base damage. The 
generation of double-strand breaks triggers DNA damage response and repair pathways. Single 
strand breaks and base damage are rapidly repaired but can give rise to stalled replication forks 
[64]. The main two repair pathways for double strand breaks are homologous recombination and 
non-homologous end-joining. Homologous recombination uses the correct DNA sequence from 
a homologous strand of undamaged DNA, achieving high fidelity even if sequence information 
is lost at the site of the break [63; 64]. Non-homologous end-joining repairs double strand breaks 
via strand re-extension and functions predominantly during G1 when HR repair is not available 
[63; 65]. Successful repair of DNA lesions will allow the cell to continue in the cell cycle but 
unsuccessful repair can trigger the death of the damaged cells, and uncorrected repair will 
generate mutations [63; 66]. Biochemical modifications that occur after radiation exposure are 
not only caused by the IR itself. Cellular damage is also caused by oxidative changes, which may 
continue to arise for days and months after the initial exposure, likely due to continuous 
generation of reactive oxygen species (ROS) [26; 67]. IR can generate reactive chemical species 
through radiolysis of water in the cells and by stimulation of oxidases and nitric oxide synthase 
(Figure 1) [26]. ROS that are directly or indirectly created by IR that exist in an aerobic cellular 
environment at physiological pH are O2•-, •OH and H2O2 [26; 68]. ROS derived from water in the 
cell damage DNA via a variety of mechanisms, including base damage, base release, 
depolymerization, cross-linking, and strand breakage [63; 69]. As well as directly causing DNA 
damage •OH generated by IR may also induce oxidative damage of the mitochondria through 
peroxidation of mitochondrial inner membrane phospholipids, resulting in enhanced generation 
of O2•- from the mitochondria and persistent oxidative stress caused by IR [70].  
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Figure 1. Direct and indirect effects of ionizing radiation on the cell. Ionizing radiation can directly 
disrupt atomic structures and produce chemical and biological changes.  Ionizing radiation can also act 
indirectly through radiolysis of cellular water and generation of ROS [26]. 
 
 The detrimental or beneficial effects of IR depends on LET and dose. Increasing LET 
causes an increase in the yield of H2O2. Also, O2•- is the most abundant radical species produced 
by radiations with high LET [26; 71; 72]. A high whole body dose (WBD) of IR, which can be 
defined as >500 mGy, delivered at a high dose rate may cause acute radiation syndrome. The 
severity of clinical signs and symptoms of acute radiation syndrome are the body volume 
irradiated, the inhomogeneity of dose exposure, the absorbed dose, the dose rate and the particle 
type [73]. A whole body dose of 1-4 Gy will cause mild to moderate symptoms, 4-8 Gy will 
cause severe to very severe symptoms, and >8 Gy is lethal [73; 74]. Acute radiation syndrome is 
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usually only caused by nuclear accidents, atomic bombs or irradiation as part of  cancer therapy 
[73]. The use of ionizing radiation has become common practice in medical diagnostics and 
cancer treatment. It is estimated that more than 50% of patients with cancer are treated with 
radiotherapy [75]. From the early 1980’s to 2006 the average radiation dose per individual in the 
United States increased by a factor of 1.7-6.2 mSv, which is believed to be caused by the growth 
of medical imaging procedures [76]. As the use of IR in medical procedures increases it is 
important to understand the biological effects it may lead to in the future.  
 
 The heart is an organ that is particularly susceptible to radiation induced damage. High 
doses of whole body radiation used in cancer treatment has been shown to lead to cardiac stress 
and cardiovascular disease (CVD) [75]. Radiation induced CVD can include pericarditis, 
myocardial fibrosis and coronary artery disease (CAD) [77-79]. Chronic or delayed pericarditis 
may occur anywhere from a few months to years after completion of radiation treatment; with up 
to 20% of patients developing symptoms of chronic pericarditis within 10 years following 
irradiation [80]. However, most of the time symptoms are present within 12 months of therapy 
[81]. Myocardial fibrosis is usually seen at radiation doses above 30 Gy and is often 
asymptomatic and can occur without an inflammatory reaction. In this case radiation leads to 
reduced myocardial compliance through microvascular insufficiency and ischemia, resulting in 
diffuse and patchy interstitial fibrosis [80]. Radiation induced CAD resembles CAD caused by 
atherosclerosis but has been shown to lead to plaque that is more fibrous with a decrease in lipid 
component [77; 80]. Also, valvular lesions and calcification have been described in irradiated 
patients [77; 82]. It is believed that coronary lesions caused by radiation therapy may be the most 
significant cause of mortality from radiation induced heart disease [81]. The majority of radiation 
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induced cardiovascular disease is caused by radiation treatment of cancer. Cancer patients treated 
with radiation as children and adolescents appear to have a high relative risk of fatal 
cardiovascular complications when compared to non treated in the same age group [83; 84]. 
Adult patients who receive radiation therapy for cancer treatment, particularly breast cancer, are 
also at risk of developing heart disease. Early Breast Cancer Trialists’ Collaborative Group data 
has shown that relative risk of cardiac death is related to the estimated mean cardiac dose, and 
that risk is increased by 3% per Gy [77]. Survivors of acute radiation syndrome also have been 
shown to develop cardiovascular disease several years after exposure. Studies with survivors of 
the atomic bombs in Hiroshima and Nagasaki have shown there is a risk of developing 
cardiovascular disease [76; 85]. Mortality from myocardial infarction 40 years after the radiation 
exposure is significantly increased in these survivors [76; 85].  
 
 Since IR causes an increase in oxidative stress, antioxidants may provide protection and 
prevent cellular damage. A complex dietary supplement consisting of a wide range of antioxidant 
and anti-inflammatory compounds has prominently been shown to increase longevity, decrease 
markers of ageing and impart protection against oxidative stress and inflammation [86-88]. 
Development of radio-protective diets is a high priority for patients or individuals exposed to IR 
[88]. The dietary supplement was designed to ameliorate several processes including oxidative 
stress, inflammatory processes, insulin resistance and mitochondrial dysfunction. Criteria for 
selecting specific ingredients for the supplement were based on scientifically documented 
evidence of beneficial effects for one or more of the targets, oral administration and approved for 
human use [89]. In an age accelerated mouse model that received a WBD of 2 Gy the dietary 
supplement prevented the formation of chromosomal aberrations. γH2AX and 8-OHdG levels 
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were significantly reduced in groups that received the supplement when compared to irradiated 
groups, suggesting that the diet scavenged free radicals before they could cause damage [88]. A 
similar study investigated the effect of the diet on radiation induced apoptosis in an age 
accelerated mouse model. Lymphocytes exposed to 2 Gy γ radiation isolated from male mice 
that received the supplementary diet showed a decrease in amount of apoptotic cells when 
compared to cells from mice that did not receive the supplement. Interestingly, lymphocytes 
from female mice were highly radiation resistant compared to males and the supplement 
provided no additional benefits, suggesting that the effects of IR can depend on several factors 
including genotype and gender [89]. It is clear the supplementary diet reduces damage caused by 
IR induced oxidative stress, whether this supplement can provide protection specifically to the 
heart against IR remains to be seen.  
 
 The objectives of this study were to examine the effects of high dose whole body 
radiation on cardiac oxidative stress and correlate it to cell death. Also, to determine if a dietary 
supplement designed to offset oxidative stress and inflammation can alter radiation-induced 
cardiac tissue damage. A mouse model was used and were fed the supplement before and after a 
WBD of 5 Gy. Previous studies have shown the supplement provides protection against IR if fed 
before exposure [88; 89] and we were interested if it can also provide protection after radiation 
exposure. We were also interested in how long the supplement can protect after radiation. 
Specifically, our focus was on antioxidants and markers of apoptosis and autophagy to provided 
insight in the mechanism(s) of radiation induced cardiac damage and protection provided from 
the dietary supplement. 
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Materials and Methods 
Animals 
 Eight week old male C57BL/6 were purchased from Jackson Laboratories and left for 7 
days to recover from transport. Mice were individually housed in 27 x 12 x 15.5 cm cages 
containing woodchip bedding (Harlan Sani-Chips, 7090). A stainless steel hopper provided food 
ad libitum (Harlan Teklad 8640 22/5 rodent chow) and supported a water bottle. Mice were 
weighed weekly midway through the photoperiod. The housing room maintained a 12:12-h 
light:dark photoperiod at 22 ± 2°C. All protocols were approved by the Animal Research Ethics 
Board at McMaster University and carried out according to the Canadian Council on Animal 
Care regulations. Mice were placed in 5 groups, 5 mice per group, identified as: 
1) Control  
2) Supplement only  
3) 5 Gy whole body dose (WBD) 
4) Supplement + 5 Gy WBD + Supplement  
5) 5 Gy WBD + Supplement  
All supplement fed mice, except for the 5 Gy WBD + Supplement group, were fed the 
supplement for 30 days prior to irradiation to allow the compounds within the supplement to 
reach equilibrium at maximal physiological levels. The 5 Gy WBD + Supplement mice were 
only fed the supplement after irradiation until their respective time points. Mice were harvested 
at each of the following time points: 48 hours, 30 days and 120 days post irradiation. Mice were 
anesthetized with isoflurane and exsanguinated via cardiac puncture. Tissue harvesting followed 
cervical dislocation, which was performed post blood collection. Tissue collected included heart, 
liver, kidneys, adrenals, brain, thymus and lungs, which were flash frozen in liquid nitrogen. 
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Bone marrow and liver, kidneys, adrenals, brain, thymus and lungs remained at McMaster 
University for future analysis, and hearts were shipped to Lakehead University. Both 30 day and 
120 day mice were tested in a novel object/place recognition and modified 8-arm radial maze for 
cognitive assessment, grip strength and balance tests. Identical tissue harvest as 48h mice 
followed immediately following completion of testing.  
 
Dietary supplement 
 Dosages of each component were calculated based on amounts commonly prescribed to 
humans (Table 1). Values were adjusted for the difference in body size and then increased by a 
factor of 10 in consideration of the higher gram-specific metabolic rate (and faster nutrient 
utilization) of mice. Supplement was made for 45 mice for 30 days at a time. Bagels were cut 
into 1 cm x 1 cm and the crust was removed. All dry components were mixed together before 
addition of oils. Oils were added and mixed into dry components and dH2O was added slowly to 
avoid clumping; 2 mL of this mixture was enough for 6 bagel pieces. Bagel pieces were pre-
soaked with 100 mL of dH2O before addition of supplement. 350 µL of supplement was added to 
each bagel piece allowed to dry overnight in a fumehood. Dry bagels were sealed in a air free 
bag and stored in a cool, dark area. Each mouse received one piece of dried bagel daily either 
with or without the supplement, depending on the treatment group. The mice were given the 
bagel pieces midway through the photoperiod. Amount of bagel eaten was measured the 
following day. 
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Table 1. Components of a Complex Dietary Supplement and Associated Cellular Targets 
 
Irradiation 
 During irradiation, mice were placed in a polyvinyl chloride (PVC) tube (5 x 12.5 cm) 
with PVC mesh end caps. To reduce stress, mice were habituated to the restraint devices 30 days 
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prior to irradiation. Each mouse was given a 5Gy whole-body dose of gamma radiation from a 
cesium-137 source (Taylor Cesium Source). After irradiation, each mouse was returned to its 
housing cage. Non-irradiated sham control mice were otherwise exposed to exactly the same 
conditions as irradiated mice. 
 
Total protein assay 
 Frozen hearts were washed in cold PBS on ice. Atria was removed and hearts were 
weighed. ~50 mg of tissue was used to collect protein samples. Hearts were lysed using Pathscan 
buffer (25mM Tris, 150mM NaCl, 1mM EDTA and 2mL Triton-X) containing sodium fluoride, 
sodium orthovanadate and protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) and kept 
on ice. Upon addition of ice-cold lysis buffer tissue samples were placed in a Tissue Lyser 
(Qiagen, Hilden, Germany) for 3 minutes at 30.0 frequency. Lysates were then centrifuged for 10 
minutes at 8000 x g. Supernatant was collected and stored at - 80 °C. The amount of protein was 
measured via a Lowry-based protein assay. Using the DC Protein Assay (Bio-Rad, Hercules, 
CA) ‘microplate’ method, which requires 5 μL of protein lysate, full-strength and 1/50-strength 
samples were measured alongside a range of bovine serum albumin (BSA; Fisher Scientific, 
Hampton, NH) standard concentrations from 0.5-4 mg/mL. Following a 15-minute colour-
development period, standard and sample absorbance was measured spectrophotometrically at a 
wavelength of 750 nm using a PowerWave XS Microplate Spectrophotometer (BioTek, 
Winooski, VT). Microsoft Excel was used to create a standard curve from the BSA standards, 
and the equation of the line of best fit was used to calculate the sample protein concentrations. 
The amount of lysate needed to equal 50 μg/well was calculated. 
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Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
  10 μL of 2x SDS sample loading buffer containing ß-mercaptoethanol (Sigma-Aldrich) 
was added to the 50 μg sample lysates and dH2O was used to give a total of 20 μL per sample. 
Samples were then placed in a 95 °C heat block for 5 minutes and then on ice for an additional 5 
minutes. Boiled lysates were quick-spun and loaded into 15 % sodium dodecyl sulfate-
polyacrylamide gels, 20 μL per well (Bio-Rad Mini PROTEAN 3 Cell System apparatus was 
used). Precision Plus Kaleidoscope (Bio-Rad) protein standard was loaded alongside the sample 
wells. Empty wells were partially filled with 2x SDS loading buffer to ensure even migration 
across the gel. The electrophoresis apparatus was filled with 1x Running buffer (standard 1x 
Running buffer was prepared from a 10x stock). Gels were run at 200 V for 1 hour or until the 
appropriate kDa range had migrated to near the centre of the gel, as indicated by reference to the 
protein standard indicator. 
 
Electrophoretic transfer 
Immediately upon completion of sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (to prevent protein band dissociation), gels were removed from the 
electrophoresis assembly, their edges trimmed and orientation marks added (i.e. diagonal edge 
cut at top-left), and then were soaked in 1x Transfer buffer for ~10 minutes for equilibration 
(standard 1x transfer buffer was prepared from a 10x stock). Nitrocellulose transfer membrane 
(GE Healthcare Life Sciences, Piscataway, NJ) was soaked in 1x transfer buffer for at least 15 
minutes. The transfer cassette was assembled as per the manufacturer’s instructions, filled with 
1x Transfer buffer, and the transfer was performed at 30 V overnight at 4° with a dH2O ice 
block. 
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Protein immunoblot and antibodies 
 Following electrophoretic transfer membranes were stained with Ponceau S solution 
(Bio-Rad) for 10 minutes to verify transfer efficiency. Excess Ponceau S stain was removed by 
dH2O. The membranes were then soaked in Tris-buffered saline containing 0.1 % Tween-20 
detergent (Sigma-Aldrich) (TBST) for 15 minutes to remove Ponceau S, followed by 3x 5 
minutes to wash and equilibrate them before being blocked with 5 % milk solution (Oxoid, 
Nepean ON) for 1 hour 30 minutes at room temperature. Blocked membranes were incubated 
with primary antibody in 5 % milk on a rocker (Boekel Scientific, Feasterville, PA) overnight at 
4 °C. β-actin (1:500), Bax (1:100) and Bcl 2 (1:100) antibodies were purchased from Santa Cruz 
Biothechnology, Santa Cruz, CA. Caspase 3 (1:500) and LC3B (1:500) antibodies from Cell 
Signaling Technology, Danvers, MA. MN-SOD (1:1000) antibody was purchased from 
Millipore (Merck KGaA, Darmstadt, Germany) and Catalase (1:5000) antibody from Sigma-
Aldrich. Membranes were then washed in TBST 3x 10 minutes. Following this step, 1:1000 
HRP-conjugated goat anti-rabbit (R&D Systems, Minneapolis, MN) or anti-mouse (Pierce 
Antibody Products, Rockford, IL) IgG secondary antibodies in 5 % milk solution were used to 
probe the membrane on a rocker for 2 hours at room temperature. Following this step, 
membranes were again washed with TBST 3x 10 minutes.  
 
Chemiluminescent imaging and densitometry 
 Standard Enhanced chemiluminescence (ECL) was performed to detect protein-banding 
patterns on the immunoblots by virtue of the HRP-conjugated secondary antibodies using 
luminol and coumeric acid (Sigma-Aldrich). Chemiluminescent immunoblots were detected via 
5-minute High-Sensitivity Chemiluminescent exposures using a Chemidoc XRS imager (Bio-
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Rad) supported by Quantity One software for Windows (Bio-Rad). Brief Epi-White exposures 
were also collected in order to interpret chemiluminescent banding patterns with the membranes’ 
visible protein ladders. Blots were analyzed via densitometry using the Quanity One software, 
with reference to β-actin control. 
 
Statistics 
 Data were presented as mean ± standard error of the mean (SEM), and all data presented 
here represents n = 5 independent experiments. Statistical analyses were performed using 
GraphPad Prism software. One-way ANOVA with post hoc Tukey’s test were utilized when 
possible with p < 0.05 considered significant. Asterisks are used herein to denote significance 
according to the following scheme: * = p < 0.05; ** = p < 0.01; *** = p < 0.001. 
 
Results  
 
Protein levels of Catalase After Radiation and Supplement Treatment 
 48 hours after a 5Gy WBD of radiation protein concentration of catalase did not change 
(Figure 2). Supplement treatment alone also did not change catalase levels when compared to 
control (Figure 2). When mice were pretreated for 30 days before irradiation and sacrificed 48 
hours after catalase increased when compared to control and 5Gy (Figure 2). When mice were 
pretreated for 30 days before and treated once 24 hours after irradiation with supplement catalase 
increased when compared to control and 5Gy (Figure 2). 30 days after radiation treatment 
protein concentration of catalase did not change (Figure 3). Supplement treatment alone did not 
change catalase levels when compared to control (Figure 3). When mice were pretreated for 30 
days before irradiation and sacrificed 30 days after or pretreated for 30 days before and 30 days 
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after irradiation catalase did not change when compared to radiation treatment (Figure 3). 120 
days after radiation treatment protein concentration of catalase (Figure 4) increased. Supplement 
treatment alone did not change catalase levels when compared to control (Figure 4). When mice 
were pretreated for 30 days before irradiation and sacrificed 120 days after or pretreated for 30 
days before and 120 days after irradiation catalase did not change when compared to radiation 
treatment (Figure 4). Catalase levels were increased in hearts of 30 day pre and 120 day post 
treated mice when compared to control (Figure 4). 
 
Protein levels of Mn-SOD After Radiation and Supplement Treatment 
 48 hours after a 5Gy WBD of radiation protein concentration of Mn-SOD decreased 
when compared to control (Figure 5). Supplement treatment alone did not change Mn-SOD 
levels when compared to control (Figure 5). When mice were pretreated for 30 days before 
irradiation and sacrificed 48 hours after Mn-SOD increased when compared to 5Gy and was 
unchanged when compared to control (Figure 5). When mice were pretreated for 30 days before 
and treated once 24 hours after irradiation with supplement Mn-SOD increased when compared 
to 5Gy and was unchanged when compared to control (Figure 5). 30 days after radiation 
treatment protein concentration of Mn-SOD decreased when compared to control (Figure 6). 
Supplement treatment alone did not change Mn-SOD levels when compared to control (Figure 
6). When mice were pretreated for 30 days before irradiation and sacrificed 30 days after or 
pretreated for 30 days before and 30 days after irradiation Mn-SOD did not change when 
compared to radiation treatment (Figure 6). Mn-SOD levels were decreased in hearts of 30 day 
pre and post treated mice when compared to control (Figure 6). 120 days after radiation 
treatment protein concentration of Mn-SOD did not change when compared to control (Figure 7). 
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Supplement treatment alone did not change Mn-SOD levels when compared to control (Figure 
7). When mice were pretreated for 30 days before irradiation and sacrificed 120 days after or 
pretreated for 30 days before and 120 days after irradiation Mn-SOD did not change when 
compared to radiation treatment (Figure 7). 
 
Protein levels of Markers of Apoptosis After Radiation and Supplement Treatment 
 Pro-caspase 3 and Bax:Bcl2 ratio were used as indicators of apoptosis. 48 hours after a 
5Gy WBD of radiation protein concentration of pro-caspase 3 and Bax:Bcl2 ratio increased when 
compared to control (Figure 8 & 11). Supplement treatment alone increased both pro-caspase 3 
and Bax:Bcl2 ratio when compared to control (Figure 8 & 11). When mice were pretreated for 30 
days before irradiation and sacrificed 48 hours after or pretreated for 30 days before and treated 
once 24 hours after irradiation with supplement pro-caspase 3 and Bax:Bcl2 ratio decreased when 
compared to radiation treatment and did not change when compared to control (Figure 8 & 11). 
30 days after radiation treatment protein concentration of pro-caspase 3 increased (Figure 9) but 
Bax:Bcl2 ratio did not change when compared to control (Figure 12). Supplement treatment 
alone did not change apoptosis protein levels when compared to control (Figure 9 & 12). When 
mice were pretreated for 30 days before irradiation and sacrificed 30 days after pro-caspase 3 did 
not change (Figure 9) while Bax:Bcl2 ratio increased when compared to 5Gy radiation treated 
and control mice (Figure 12). Hearts from mice treated with supplement 30 days before and after 
irradiation showed decreased protein levels of pro-caspase 3 (Figure 9) and increased Bax:Bcl2 
ratio when compared to radiation treatment (Figure 12). Pro-caspase 3 did not change (Figure 9) 
while Bax:Bcl2 ratio increased when compared to control mice (Figure 12). 120 days after 
radiation treatment protein concentration of pro-caspase 3 increased (Figure 10) while Bax:Bcl2 
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ratio did not change when compared to control (Figure 13). Supplement treatment alone did not 
change protein levels of pro-caspase 3 when compared to control (Figure 10) but did decrease 
Bax:Bcl2 ratio (Figure 13). When mice were pretreated for 30 days before irradiation and 
sacrificed 120 days after pro-caspase 3 did not change (Figure 10) while Bax:Bcl2 ratio 
decreased when compared to radiation treated mice (Figure 13). When compared to control pro-
caspase 3 was increased (Figure 10) and Bax:Bcl2 ratio was decreased (Figure 13). When mice 
were pretreated for 30 days before and 120 days after irradiation with supplement pro-caspase 3 
decreased (Figure 10) while Bax:Bcl2 ratio did not change when compared to 5Gy radiation 
treated mice (Figure 13). There was no change in protein levels of pro-caspase 3 or Bax:Bcl2 
when compared to control (Figure 10 & 13). 
 
Protein levels of Autophagy Marker After Radiation and Supplement Treatment  
 LC3bII:I ratio was used as an indicator of autophagy. 48 hours after a 5Gy WBD of 
radiation protein concentration of LC3bII:I ratio did not change when compared to control 
(Figure 14). Supplement treatment alone did not change LC3bII:I ratio when compared to control 
(Figure 14). When mice were pretreated for 30 days before irradiation and sacrificed 48 hours 
after or pretreated for 30 days before and treated once with supplement 24 hours after irradiation 
LC3bII:I ratio increased when compared to 5Gy treated mice and control (Figure 14). There was 
no change in LC3bII:I ratio after radiation alone or any of the supplement treated mice in the 30 
day treatment groups when compared to control (Figure 15). 120 days after radiation treatment 
LC3bII:I ratio increased when compared to control (Figure 16). Supplement treatment alone did 
not change LC3bII:I ratio when compared to control (Figure 16). When mice were pretreated for 
30 days before irradiation and sacrificed 120 days after LC3bII:I ratio did not change when 
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compared to radiation treated mice and was increased when compared to control (Figure 16).  
When mice were pretreated for 30 days before and 120 days after irradiation LC3bII:I ratio 
decreased compared to radiation treated mice to near control levels (Figure 16). 
 
Conclusion 
 
 The heart is particularly susceptible to radiation induced oxidative stress. A dietary 
supplement was able to provide, in some cases, protection to the heart with regard to protein 
expression of antioxidants and markers of apoptosis and autophagy. This protection and extent of 
radiation induced damage appears to be dependent on time.  
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Figure 2.  The effect of a dietary supplement on catalase protein expression in the heart at 
48 hours after 5 Gy whole body radiation. Protein concentration of catalase was assessed via 
immunoblotting, where C = control, S = supplement alone, 5Gy = single whole body dose of 5 
Gy γ radiation, S+5Gy+S = supplement for 30 days prior radiation and 48 hours after, 5Gy+S = 
supplement 48 hours after radiation. Bars represent mean ± SEM where n = 5 (** = p < 0.01 
versus control; * = p < 0.05 versus control; ^ = p < 0.05 versus 5 Gy). 
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Figure 3.  The effect of a dietary supplement on catalase protein expression in the heart at 
30 days after 5 Gy whole body radiation. Protein concentration of catalase was assessed via 
immunoblotting, where C = control, S = supplement alone, 5Gy = single whole body dose of 5 
Gy γ radiation, S+5Gy+S = supplement for 30 days prior radiation and 30 days after, 5Gy+S = 
supplement 30 days after radiation. Bars represent mean ± SEM where n = 5. 
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Figure 4.  The effect of a dietary supplement on catalase protein expression in the heart at 
120 days after 5 Gy whole body radiation. Protein concentration of catalase was assessed via 
immunoblotting, where C = control, S = supplement alone, 5Gy = single whole body dose of 5 
Gy γ radiation, S+5Gy+S = supplement for 30 days prior radiation and 120 days after, 5Gy+S = 
supplement 120 days after radiation. Bars represent mean ± SEM where n = 5  (** = p < 0.01 
versus control; * = p < 0.05 versus control). 
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Figure 5.  The effect of a dietary supplement on Mn-SOD protein expression in the heart at 
48 hours after 5 Gy whole body radiation. Protein concentration of Mn-SOD was assessed via 
immunoblotting, where C = control, S = supplement alone, 5Gy = single whole body dose of 5 
Gy γ radiation, S+5Gy+S = supplement for 30 days prior radiation and 48 hours after, 5Gy+S = 
supplement 48 hours after radiation. Bars represent mean ± SEM where n = 5 (* = p < 0.05 
versus control; ^^^ = p < 0.001 versus 5 Gy; ^ = p < 0.05 versus 5 Gy). 
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Figure 6.  The effect of a dietary supplement on Mn-SOD protein expression in the heart at 
30 days after 5 Gy whole body radiation.  Protein concentration of Mn-SOD was assessed via 
immunoblotting, where C = control, S = supplement alone, 5Gy = single whole body dose of 5 
Gy γ radiation, S+5Gy+S = supplement for 30 days prior radiation and 30 days after, 5Gy+S = 
supplement 30 days after radiation. Bars represent mean ± SEM where n = 5 (** = p < 0.01 
versus control). 
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Figure 7.  The effect of a dietary supplement on Mn-SOD protein expression in the heart at 
120 days after 5 Gy whole body radiation.  Protein concentration of Mn-SOD was assessed via 
immunoblotting, where C = control, S = supplement alone, 5Gy = single whole body dose of 5 
Gy γ radiation, S+5Gy+S = supplement for 30 days prior radiation and 120 days after, 5Gy+S = 
supplement 120 days after radiation. Bars represent mean ± SEM where n = 5. 
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Figure 8.  The effect of a dietary supplement on Pro-caspase 3 protein expression in the 
heart at 48 hours after 5 Gy whole body radiation. Protein concentration of pro-caspase 3 was 
assessed via immunoblotting, where C = control, S = supplement alone, 5Gy = single whole 
body dose of 5 Gy γ radiation, S+5Gy+S = supplement for 30 days prior radiation and 48 hours 
after, 5Gy+S = supplement 48 hours after radiation. Bars represent mean ± SEM where n = 5 (** 
= p < 0.01 versus control; ^^^ = p < 0.001 versus 5 Gy; ^ = p < 0.05 versus 5 Gy). 
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Figure 9.  The effect of a dietary supplement on Pro-caspase 3 protein expression in the 
heart at 30 days after 5 Gy whole body radiation. Protein concentration of pro-caspase 3 was 
assessed via immunoblotting, where C = control, S = supplement alone, 5Gy = single whole 
body dose of 5 Gy γ radiation, S+5Gy+S = supplement for 30 days prior radiation and 30 days 
after, 5Gy+S = supplement 30 days after radiation. Bars represent mean ± SEM where n = 5  (** 
= p < 0.01 versus control; ^^ = p < 0.01 versus 5 Gy). 
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Figure 10.  The effect of a dietary supplement on Pro-caspase 3 protein expression in the 
heart at 120 days after 5 Gy whole body radiation. Protein concentration of pro-caspase 3 was 
assessed via immunoblotting, where C = control, S = supplement alone, 5Gy = single whole 
body dose of 5 Gy γ radiation, S+5Gy+S = supplement for 30 days prior radiation and 120 days 
after, 5Gy+S = supplement 120 days after radiation. Bars represent mean ± SEM where n = 5  
(** = p < 0.01 versus control; * = p <0.05 versus control; ^ = p < 0.05 versus 5 Gy). 
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 Figure 11.  The effect of a dietary supplement on Bax/Bcl2 ratio protein expression in the 
heart at 48 hours after 5 Gy whole body radiation. Protein concentration of Bax/Bcl2 ratio 
was assessed via immunoblotting, where C = control, S = supplement alone, 5Gy = single whole 
body dose of 5 Gy γ radiation, S+5Gy+S = supplement for 30 days prior radiation and 48 hours 
after, 5Gy+S = supplement 48 hours after radiation. Bars represent mean ± SEM where n = 5  
(*** = p < 0.001 versus control; ^^^ = p < 0.001 versus 5 Gy). 
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Figure 13.  The effect of a dietary supplement on Bax/Bcl2 ratio protein expression in the 
heart at 30 days after 5 Gy whole body radiation. Protein concentration of Bax/Bcl2 ratio was 
assessed via immunoblotting, where C = control, S = supplement alone, 5Gy = single whole 
body dose of 5 Gy γ radiation, S+5Gy+S = supplement for 30 days prior radiation and 30 days 
after, 5Gy+S = supplement 30 days after radiation. Bars represent mean ± SEM where n = 5  (^^ 
= p < 0.01 versus 5 Gy). 
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Figure 15.  The effect of a dietary supplement on Bax/Bcl2 ratio protein expression in the 
heart at 120 days after 5 Gy whole body radiation. Protein concentration of Bax/Bcl2 ratio 
was assessed via immunoblotting, where C = control, S = supplement alone, 5Gy = single whole 
body dose of 5 Gy γ radiation, S+5Gy+S = supplement for 30 days prior radiation and 120 days 
after, 5Gy+S = supplement 120 days after radiation. Bars represent mean ± SEM where n = 5  
(*** = p < 0.001 versus control; ^ = p < 0.05 versus 5 Gy). 
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Figure 14.  The effect of a dietary supplement on LC3bII/LC3bI ratio protein expression in 
the heart at 48 hours after 5 Gy whole body radiation. Protein concentration of 
LC3bII/LC3bI ratio was assessed via immunoblotting, where C = control, S = supplement alone, 
5Gy = single whole body dose of 5 Gy γ radiation, S+5Gy+S = supplement for 30 days prior 
radiation and 48 hours after, 5Gy+S = supplement 48 hours after radiation. Bars represent mean 
± SEM where n = 5 (*= p < 0.05 versus control; ^ = p < 0.05 versus 5 Gy). 
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Figure 15.  The effect of a dietary supplement on LC3bII/LC3bI ratio protein expression in 
the heart at 30 days after 5 Gy whole body radiation. Protein concentration of LC3bII/LC3bI 
ratio was assessed via immunoblotting, where C = control, S = supplement alone, 5Gy = single 
whole body dose of 5 Gy γ radiation, S+5Gy+S = supplement for 30 days prior radiation and 30 
days after, 5Gy+S = supplement 30 days after radiation. Bars represent mean ± SEM where n = 
5. 
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Figure 16.  The effect of a dietary supplement on LC3bII/LC3bI ratio protein expression in 
the heart at 120 days after 5 Gy whole body radiation.Protein concentration of LC3bII/LC3bI 
ratio was assessed via immunoblotting, where C = control, S = supplement alone, 5Gy = single 
whole body dose of 5 Gy γ radiation, S+5Gy+S = supplement for 30 days prior radiation and 120 
days after, 5Gy+S = supplement 120 days after radiation. Bars represent mean ± SEM where n = 
5 (*** = p < 0.001 versus control; ** = p < 0.01 versus control; ^ = p < 0.05 versus 5 Gy). 
 
47 
 
Chapter 3 - Impact of High Dose Radiation 
to the Brain on Cardiac Function 
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Abstract 
 
 There is increasing evidence that suggests that radiation may induce DNA damage at 
sites that are distant from the irradiated target, referred to as the abscopal effect. There are very 
few studies on the abscopal effect and the heart. We investigated if a high dose of radiation to the 
head can lead to damage to the heart. Also, we investigated if a complex dietary supplement can 
attenuate the potential cardiac damage caused by the radiation. Eight week old male Thy1-GFP 
mice were fed the supplement 30 days before and after radiation or for just 30 days after. 
Radiation was given as a single 10 Gy dose to the brain. Hearts were collected and fixed in 
formalin. Hearts were then embedded in paraffin and sectioned at 5 µm at the mid papillary 
level. Histological staining with Hematoxylin and Eosin, Masson's Trichrome and Picrosirius 
Red was performed to evaluate inflammation and fibrosis. There was no significant difference in 
the amount of cardiac inflammation or fibrosis between any of the treatment groups. Therefore, a 
10 Gy dose to the brain may not have an effect on cardiac inflammation or fibrosis, at least not 
within the timeframe of this study. It remains to be seen if a complex dietary supplement can 
protect against radiation induced damage due to the abscopal effect.      
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Introduction 
 
 In addition to oxidative stress, ionizing radiation has also been shown to induce an 
increase in inflammation. Inflammation, like oxidative stress, has both beneficial and detrimental 
effects and is implicated in several cardiac disease conditions. The inflammatory response is an 
integral component of the host response to tissue injury or invasion but also plays a particularly 
active role after myocardial infarction. Myocardial stress in the setting of ischemia will rapidly 
induce cytokines production as a response to oxidative stress [90]. Cytokines are also more 
implicated in the host’s immune response to infections and other forms of stresses. Tumor 
necrosis factor-alpha (TNF-α) is a pro-inflammatory cytokine that plays an important role in the 
heart. It can stimulate antigen presentation, inflammatory cell activity, expression of matrix-
degrading enzymes and initiate apoptosis [91-93]. ROS are known to initiate the inflammatory 
response and cause an increase in TNF-α production. H2O2 can directly induce myocardial TNF 
production via the p38 MAPK pathway [90; 94]. TNF-α and other pro-inflammatory mediators 
contribute to the production of ROS, which further stimulates the production of TNF-α, causing 
a perpetuating 'vicious cycle' [45]. Studies in irradiated tumors have shown that radiation can up-
regulate the expression of inflammatory mediators TNF-α and intercellular adhesion molecule 
(ICAM)-1 [95-98]. A study by Azimzadeh et al. [99] indicated that total body irradiation can 
immediately induce cardiac inflammation. Various inflammatory and antioxidative defense 
proteins were altered when compared to non-irradiated controls. Up-regulation of cytokines such 
interleukin (IL)-6 and IL-8 has been observed after endothelial cell irradiation in a time and dose 
dependent manner [78; 100].  
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 TNF-α, have been shown play an important role in regulating collagen deposition post 
myocardial infarction [90]. A study of a rat model of myocardial infarction found the expression 
of TNF-α, IL-1β, IL-6, transforming growth factor (TGF)-β1, and TGF-β3 increased after 1 
week after myocardial infarction [90; 101]. Elevated cytokines also promote interstitial fibrosis 
and collagen deposition. There are many types of collagen but the majority of the collagen in the 
body consists of types I, II, and III. Type I is present in scar tissue, skin, tendons and organs. 
Type II is found in cartilage. Type III is commonly found with Type I. Type IV is found in 
basement membranes and used for support [102]. Collagen types I and III are most abundant in 
the myocardium [103]. Increased cytokines, including  IL-1β, TNF-α, IL-6 and TGF-β, have 
been shown correlate closely to the deposition of type I and type III collagens [90; 104]. This is 
due to the role of cytokines in the remodeling process. Matrix metalloproteinases (MMP) are 
synthesized in inflammation and participate in tissue remodeling. MMPs are generally secreted 
in an inactive form but can be readily activated within minutes of ischemia by cytokines and 
even ROS, leading to collagen degradation and, subsequently, matrix deposition [90]. TNF-α can 
also lead to enhanced angiotensin II-mediated effects in favor of fibrosis [90; 105]. Premature 
differentiation of fibroblasts to myofibroblasts can be induced by ionizing radiation [106]. In 
hearts from rats that received 15 Gy or 18 Gy γ radiation to the chest, histological staining 
revealed significant myocardial fibrosis, degeneration and necrosis when compared to the 
controls [107]. Another study using 10 Gy whole body irradiation examined the impact of high 
dose radiation on coronary microvasculature and ventricular function in rats. Radiation exposure 
resulted in cellular peri-arterial fibrosis and irregular collagen deposition [108]. Myocardial cells 
appear to be sensitive to radiation-induced fibrosis as observed by many reports of arrhythmias 
occurring after chest radiotherapy [83; 109; 110] 
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 Increasing evidence indicates that inflammatory cells in circulating blood of patients that 
received irradiation may also induce DNA damage at sites that are distant from the irradiated 
target, contributing to abscopal effects [26]. It is used to describe the distant tumor regression 
seen after localized therapeutic irradiation in a different area [111]. The abscopal effect is poorly 
understood but is believed to be in part immune-mediated. During treatment radiation induces an 
inflammatory response in tumor tissue that leads to cell death. It has been suggested that this cell 
death leads to further release of inflammatory cytokines which may be responsible for the 
abscopal effect after therapy [112-115]. Studies in the Japanese atomic bomb survivors revealed 
changes in lymphocyte subpopulations patterns and increased levels of parathyroid hormone, 
both have which might have contributed to the development of cardiovascular disease due to 
abscopal effects [78; 116; 117]. Oxidative-stress mediators have also been implicated in abscopal 
effects. These effects may be mediated by redox-sensitive cytokines that are both cytotoxic as 
well as capable of mediating an antitumor effect by activation of immune activity [26; 118]. It 
was found that after partial irradiation of rat lung micronucleus formation was observed in other 
non-irradiated areas of the lung. Pre-treatment with SOD led to a reduced response in the 
shielded area, indicating the involvement of ROS [111; 119]. While the abscopal effect has been 
described in various studies, it is rarely recognized as a clinical event [112]. Also, there has been 
very little study on its effects on the heart. 
 
 The objectives of this study were to investigate a possible abscopal effect on the heart 
after a high dose of radiation to the head in terms of inflammation and fibrosis. Also, to 
determine if a dietary supplement composed of antioxidants and anti-inflammatories can offset 
cardiac inflammation and fibrosis caused by the abscopal effect. Levels of inflammation and 
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fibrosis was measured using histochemistry staining of formalin fixed hearts. There has been no 
previous studies on cardiac injury induced by a high dose of radiation to the head, therefore this 
study will provide novel insight on the heart and the abscopal effect. 
   
Materials and Methods 
Animals 
 Eight week old male Thy1-GFP mice were purchased from Jackson Laboratories and left 
for 7 days to recover from transport. These mice contained green fluorescent protein expression 
in the Thy1 promoter region. Thy1 is expressed in neurons therefore the brain expresses the 
green fluorescence. Dendrite size, number and complexity will be examined at the University of 
California, Irvine. Mice were individually housed in 27 x 12 x 15.5 cm cages containing 
woodchip bedding (Harlan Sani-Chips, 7090). A stainless steel hopper provided food ad libitum 
(Harlan Teklad 8640 22/5 rodent chow) and supported a water bottle. Mice were weighed 
weekly midway through the photoperiod. The housing room maintained a 12:12-h light:dark 
photoperiod at 22 ± 2°C. All protocols were approved by the Animal Research Ethics Board at 
McMaster University and carried out according to the Canadian Council on Animal Care 
regulations. Mice were placed in 6 groups, 7 mice per group, identified as: 
1) Control 
2) Supplement only  
3) 10 Gy to the brain only 
4) Supplement + 10 Gy Brain  
5) 10 Gy Brain + Supplement  
6) Scatter dose (WBD equivalent to scatter from 10 Gy inside shield) 
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All supplement fed mice, except for the 10 Gy + Supplement group, were fed the supplement for 
30 days prior to irradiation to allow the compounds within the supplement to reach equilibrium 
at maximal physiological levels. 10 Gy + Supplement mice were only fed the supplement for 30 
days post irradiation. Animals were transferred to a nose cone containing 3% Isoflurane and loss 
of sensory/reflex response was confirmed by toe pinch. Animals were be immobilized in a 
drainage pan by extending and taping the forelimbs and securing the torso just above the 
hindlimbs. The abdominal skin was cut at the level of the diaphragm. The chest cavity was 
exposed by cutting across the diaphragm and through the ribs, making 2 cuts to free the sternum 
from ribcage and clamp open to expose the heart and allow drainage of fluids. A blunted 23-
gauge winged needle was inserted directly into the left ventricle and saline containing 0.9% 
heparin was infused using a gravity fed IV set-up, using sharp scissors, cut the right auricle to 
allow fluid drainage and perfuse until the fluid exiting the heart ran clear. Perfusion fluid was 
changed to 4% paraformaldehyde solution and approximately 75ml of fixative was perfused into 
each mouse. Mice were decapitated and the top of the skull was cut along the midline to allow 
removal of the intact brain. The brain and heart were fixed in 4% paraformaldehyde for 24 hours 
at 4°C, and then stored in PBS containing 0.05% sodium azide at 4°C until futher analysis.    
 
Dietary Supplement 
 Dosages of each component were calculated based on amounts commonly prescribed to 
humans (Table 1). Values were adjusted for the difference in body size and then increased by a 
factor of 10 in consideration of the higher gram-specific metabolic rate (and faster nutrient 
utilization) of mice. Supplement was made for 45 mice for 30 days at a time. Bagels were cut 
into 1 cm x 1 cm and crust removed. All dry components were mixed together before addition of 
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oils. Oils were added and mixed into dry components and dH2O was added slowly to avoid 
clumping; 2 mL/6 bagel piece. Bagel pieces were pre-soaked with 100 mL of dH2O before 
addition of supplement. 350 µL of supplement was added to each bagel piece allowed to dry 
overnight in a fumehood. Dry bagels were sealed in a air free bag and stored in a cool, dark area. 
Each mouse received one piece of dried bagel daily either with or without the supplement, 
depending on the treatment group. The mice were given the bagel pieces midway through the 
photoperiod. Amount of bagel eaten was measure the following day. 
 
Irradiation 
 During irradiation, mice were restrained in a decapicone mouse restraint (Braintree 
Scientific) and held in a lead-shielded container which only exposes the head to irradiation. To 
reduce stress, mice were habituated to the restraint devices 30 prior to irradiation. Each mouse 
was given a 10 Gy dose of gamma radiation to the head from a cesium-137 source (Taylor 
Source). After irradiation, each mouse was returned to its housing cage. Non-irradiated sham 
control mice were otherwise exposed to exactly the same conditions as irradiated mice. 
 
Histochemistry 
 Formalin fixed hearts were sent to the Laboratory Services Division of the Animal Health 
Laboratory of University of Guelph for paraffin embedding, sectioning (2 sections per slide) and 
Hematoxylin and Eosin (H & E) staining. Hearts were sectioned at the mid papillary level at a 
thickness of 5 µm. Unstained sections were then stained with either Masson's Trichrome or 
Picrosirius Red. Slides were deparaffinized and rehydrated through xylene (3 x 10 minutes), 
100% alcohol (2 x 2 minutes), 95% alcohol (2 x 2 minutes), 80% alcohol (2 x 2 minutes) and 
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70% (2 x 2 minutes) alcohol washes. For Masson's Trichrome (Sigma) staining slides were re-
fixed in Bouin's solution for 1 hour in a 56°C water bath. Slides were then rinsed with running 
tap water for 10 minutes to remove yellow colour. Slides were stained in Weigert's iron 
hematoxylin working solution (Sigma) for 8 minutes to stain nuclei then rinsed in running tap 
water for 10 minutes and washed in distilled water. First, slides were placed in Biebrich scarlet-
acid fuchsin solution for 10 minutes then washed with distilled water. Second, slides were 
differentiated with phosphomolybdic-phosphotungstic acid solution for 10 minutes. Third, slides 
were placed directly to aniline blue solution and stain for 5 minutes, rinsed briefly in distilled 
water and differentiated in 1% acetic acid solution for 5 minutes. Slides were washed in distilled 
water and quickly dehydrated through 100% alcohol and cleared in xylene. A 60% dilution of 
permount (Sigma) was used to mount slides which were left overnight to dry. For Picrosirius Red 
(Sigma) staining slides were first stained in Weigert's iron hematoxylin working solution 
(Sigma) for 8 minutes to stain nuclei then rinsed in running tap water for 10 minutes and washed 
in distilled water. Slides were then stained in picrosirius red stain composed of piciric acid 
(Sigma) and  sirius red (Sigma) for 1 hour. Slides were washed in 2 changes of acidified water 
and water was removed by vigorous shaking. Slides were washed in distilled water and quickly 
dehydrated through 100% alcohol and cleared in xylene. A 60% dilution of permount (Sigma) 
was used to mount slides which were left overnight to dry. Images at 100x magnification were 
captured using microscope (OMAX MD827S30L, OMAX, Kent, WA) and camera (ScopeImage 
9.0, BioImager Inc., Toronto, ON). Images were analyzed via ImageJ (using the k-means 
clustering segmentation plugin. Percentage of positive staining was calculated based on number 
of colour-of-interest pixels by number of total pixels of the whole section. 
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Statistics 
 Data were presented as mean ± standard error of the mean (SEM), and all data presented 
here represents n ≥ 5 independent experiments. Statistical analyses were performed using 
GraphPad Prism software. One-way ANOVA with post hoc Tukey’s test were utilized when 
possible with p < 0.05 considered significant. Asterisks are used herein to denote significance 
according to the following scheme: * = p < 0.05; ** = p < 0.01; *** = p < 0.001. 
 
Results 
Hematoxylin and Eosin Staining of Heart Sections 
 H & E staining did not show any difference in cell size or morphology between the 
groups, regardless of radiation or supplement treatment. Also, there was no change in the amount 
of inflammatory cells between the treatment groups (Figure 17). 
 
Masson's Trichrome Staining of Heart Sections 
 Type I collagen is seen at the late stage of the fibrotic process and can therefore be an 
indicator of chronic inflammation. Masson's Trichrome, which stains Type I collagen, was used 
to measure the percentage of inflammation per section of heart. There was no change in the 
amount of inflammation between the treatment groups (Figure 18). 
 
Picrosirius Red Staining of Heart Sections 
 Picrosirius Red, which stains Type I and III collagen, was used to measure the percentage 
of fibrosis per section of heart. There was no change in the amount of fibrosis between the 
treatment groups (Figure 19). 
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Conclusion 
  
 Evidence suggests that radiation may induce damage at sites that are distant from the  
irradiated target due to the abscopal effect. There are very few studies on the abscopal effect and  
the heart. In this study, neither a high dose of radiation to the head nor a dietary supplement had 
an effect on inflammation or fibrosis in mouse hearts. It is important to consider that our model 
may not be appropriate to see cardiac damage caused by the abscopal effect. 
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Figures 
 
 
Figure 17.  Heart sections stained with Hematoxylin and Eosin stain. Heart sections were 
stained with Hematoxylin and Eosin stain. Treatments include Control, Supplement (30 days 
before and after radiation), 10 Gy Brain (single dose to the head), Supplement + 10 Gy 
(supplement for 30 days before and after 10 Gy), 10 Gy + Supplement (supplement for 30 days 
after 10 Gy) and Scatter Dose (whole body dose equivalent to scatter from 10 Gy inside shield). 
Image representations are at 400x magnification, n = 6. 
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Figure 18.  The percentage of cardiac inflammation per section via Masson's Trichrome 
stain. Level of inflammation per section of heart stained with Masson's Trichrome stain and 
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evaluated using ImageJ. Treatments include Control, Supplement (30 days before and after 
radiation), 10 Gy Brain (single dose to the head), Supplement + 10 Gy (supplement for 30 days 
before and after 10 Gy), 10 Gy + Supplement (supplement for 30 days after 10 Gy) and Scatter 
Dose (whole body dose equivalent to scatter from 10 Gy inside shield). Image representations 
are at 400x magnification. Bars represent mean ± SEM where n = 6. 
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Figure 19.  The percentage of cardiac fibrosis per section via Picrosirius Red stain. Level of 
fibrosis per section of heart stained with Picrosirius Red stain and evaluated using ImageJ. 
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Treatments include Control, Supplement (30 days before and after radiation), 10 Gy Brain 
(single dose to the head), Supplement + 10 Gy (supplement for 30 days before and after 10 Gy), 
10 Gy + Supplement (supplement for 30 days after 10 Gy) and Scatter Dose (whole body dose 
equivalent to scatter from 10 Gy inside shield). Image representations are at 400x magnification. 
Bars represent mean ± SEM where n = 6. 
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Chapter 4 - The Effect of 
Secoisolariciresinol Diglucoside on 
Oxidative Stress and Antioxidants in 
Monocrotaline Induced Cardiac 
Dysfunction 
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Abstract 
  
 Pulmonary arterial hypertension (PAH) occurs when proliferation and remodeling of 
pulmonary arterioles leads to pulmonary vascular resistance and pulmonary arterial pressure, 
resulting in right ventricle hypertrophy leading to dilation and eventually failure. Oxidative stress 
has been implicated in the pathogenesis of PAH and may play an important role in the regulation 
of cellular signaling involved in cardiac response to pressure overload. Secoisolariciresinol 
diglucoside (SDG) is a component from flaxseed that has been shown to reduce cardiac oxidative 
stress in various pathophysiological conditions. We investigated the potential protective 
capabilities of SDG in a monocrotaline induced model of PAH. Six week old male Wistar rats 
were given a single intraperitoneal injection of monocrotaline and sacrificed 21 days later where 
right ventricles were collected. SDG was given either for 21 days (co-treatment with 
monocrotaline) or for 35 days with a pre-treatment for 14 days before monocrotaline 
administration and sacrificed 21 days later. Monocrotaline treatment led to increases in right 
ventricle hypertrophy, lipid peroxidation and plasma levels of alanine transaminase and aspartate 
transaminase. Co-treatment with SDG did not change hypertrophy or alanine transaminase and 
aspartate transaminase levels but decreased reactive oxygen species levels, catalase and 
superoxide dismutase activity compared to monocrotaline treatment. Also, pre-treatment with 
SDG decreased right ventricle hypertrophy, reactive oxygen species levels, lipid peroxidation, 
catalase, superoxide dismutase and glutathion peroxidase activity and plasma levels of alanine 
transaminase and aspartate transaminase when compared to monocrotaline treatment alone. 
These findings indicate that pre-treatment with SDG provided protection in this model of heart 
failure, suggesting an important role for SDG in PAH and right ventricular remodeling.        
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Introduction 
  
 Pulmonary hypertension is a chronic disease characterized by an elevation of mean 
pulmonary artery pressure above 25 mm Hg [120]. Currently, there are five major categories of 
pulmonary hypertension recognized; Pulmonary arterial hypertension, Pulmonary hypertension 
with left heart disease, Pulmonary hypertension associated with lung disease and/or hypoxemia, 
Pulmonary hypertension due to chronic thrombotic and/or embolic disease and Miscellaneous 
[121]. Pulmonary arterial hypertension (PAH) occurs when the proliferation and remodeling of 
pulmonary arterioles causes an increase in pulmonary vascular resistance and pulmonary arterial 
pressure [122]. This eventually leads to the development of right ventricular hypertrophy and 
congestive heart failure due to a progressive increase in pulmonary vascular resistance (PVR) 
and pulmonary arterial pressure [121; 122]. In PAH the primary vascular changes leading to 
increased PVR are vasoconstriction, remodeling of the pulmonary vascular wall and thrombosis 
[122]. Vasoconstriction is the result of endothelial dysfunction caused by an imbalance in the 
availability of dilators and an excess in constrictors [123]. Excess vasoconstrictors stimulates 
cellular proliferation of vascular smooth muscle cells and induces fibrosis [122]. Vascular 
remodeling includes medial hypertrophy and arteriole plexiform lesions resulting from intimal 
hyperplasia eventually leading to luminal occlusion and arteriolar pruning [122; 123]. As PAH 
progresses there is an increased afterload on the right ventricle promoting right ventricular 
hypertrophy. The right ventricle can compensate with enhanced contractility, but as afterload 
increases the right ventricle decompensates, resulting in right ventricle failure [123]. Risk of 
developing PAH is increased in patients with congestive heart failure, blood clots in the lungs, 
hereditary mutations, HIV, liver disease, portal hypertension and other conditions linked to high 
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blood pressure [121]. Symptoms are often nonspecific and may mimic other common disorders. 
These symptoms can include fatigue or weakness, angina, peripheral edema, and the most 
common symptom of exertional dyspnea [122].  PAH pathogenesis is complicated and it is likely 
that one factor alone is not sufficient to activate all of the necessary pathways leading to the 
development of the disease [122]. This makes it difficult to diagnose and treat the disease, and in 
fact there is currently no cure available.  
 
 PAH induced right ventricle failure is characterized by diminished myocardial perfusion 
and ischemia, increased end diastolic volume, right ventricle dilation, reduced stroke volume, 
and reduced cardiac output [123] and is defined as Cor pulmonale [124]. Initially, cardiac 
remodeling and hemodynamic and neurohumoral activation occurs [124; 125]. This results in a 
period of cardiomyocytes hypertrophy, followed by a reduction in cell number due to apoptosis 
[124; 126]. This continuous remodeling, hypertrophy and apoptosis eventually leads to heart 
failure [124; 125]. Currently there are several therapeutic options available that are targeted to 
specific molecular mechanisms of PAH. Calcium-channel blockers that act as vasodilators have 
been shown to improve survival, but is only a suitable option for patients with a positive 
vasodilator challenge, which is present in fewer than 10% of patients with PAH [121; 122; 127]. 
Protacyclins promote vasodilation and inhibit vascular proliferation and platelet aggregation and 
have been shown to lead to improvement in exercise capacity, hemodynamics, and quality of life 
[121]. Unfortunately, due to the short half life of protacyclins, treatment is done intravenously 
which may cause complications after long term therapy [122]. Endothelin antagonists block 
vasoconstrictor endothelin-1 and have been shown to improve cardiopulmonary hemodynamic 
variables but may also cause liver toxicity, anemia, edema, teratogenicity, male infertility, and 
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testicular atrophy [121; 122; 128]. Nitric oxide and phosphodiesterase inhibitors act as a 
vasodilator, platelet inhibitor, and antiproliferative agent on vascular smooth muscle cells and 
have shown to improve symptoms, but long term effects are not yet known [121; 122]. Since 
available treatments can cause adverse side effects and are not suitable for all patients, further 
study on possible treatment options for PAH are needed. 
 
 Increased production of ROS has been shown to be involved in PAH pathogenesis. 
Oxidant stress has been demonstrated in the lungs and right ventricle of several animal models of 
PAH [123]. ROS from the mitochondrial electron-transport chain promote vasculopathy through 
increased cellular senescence, necrosis, or apoptosis [129; 130]. Studies have shown that 
increases in mitochondrial-derived ROS contribute to hypoxic pulmonary vasoconstriction [129; 
131; 132]. A commonly used model of PAH is the rat monocrotaline (MCT) model. MCT is a 
pyrrolizidine alkaloid present in the plant Crotalaria spectabilis. It causes endothelial injury and 
an imbalance between vasodilators and vasoconstrictors which leads to vessel wall thickening, 
increased pulmonary resistance and right ventricle hypertrophy [133-135]. Pichardo et al. [136] 
demonstrated in right ventricles from rats treated with MCT, Vitamin E levels were decreased 
and lipid hydroperoxide concentrations were increased, indicating an increase in oxidative stress. 
Farahmand et al. [134] also reported that ROS are involved in PAH, right ventricular 
hypertrophy, and failure induced by MCT. PAH induced oxidative stress in rat cardiomyocytes 
has been shown to be due to ROS generated from NADPH oxidase and the mitochondria [137]. 
The role of ROS in PAH induced heart failure suggests that treatment with antioxidants may be 
beneficial. Studies on MCT treated rats pretreated with grape juice, which is rich in flavonoids 
and poses antioxidant properties, have shown that grape juice can offer some protection to the 
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right ventricle through decrease of lipid peroxidation, decreased cleaved caspase-3 and 
improvement of hemodynamic parameters [124; 133]. Treatment with synthetic antioxidant 
EUK-134 attenuated cardiomyocyte hypertrophy, reduced right ventricle oxidative stress, 
reduced proapoptotic signaling and prevented interstitial fibrosis in MCT treated rats [138]. 
Therefore, antioxidants may provide an useful therapeutic treatment option of PAH, but further 
studies are needed. 
 
 Flax (Linum usitatisimum) is grown as a food or fiber crop. Flaxseed is the richest source 
of a lignan called secoisolariciresinol diglucoside (SDG) [139; 140]. When ingested SDG is 
converted to aglycone secoisolariciresinol, which is structurally similar to known antioxidant 
nordihydroguaiaretic acid. Therefore, SDG can inhibit the production of ROS and remove ROS 
already produced through antioxidant and anti-platelet-activating factor-(PAF) activity [141]. 
There have been numerous studies on the effect of SDG on oxidative stress and cardiovascular 
health. In streptozotocin induced diabetic rats, treatment with SDG reduced glucose levels and 
lipid profile, restored antioxidant enzymes and improved insulin levels [142]. Pretreatment with 
SDG was able to significantly prevent the development of diabetes in streptozotocin treated rats 
[143], diabetic prone BioBreeding rats [141] and type 2 diabetes prone Zucker rats [144]. In a 
rabbit model of atherosclerosis, SDG treatment reduced the development of atherosclerotic 
lesions by causing a decrease in serum cholesterol, LDL-C, and lipid peroxidation product and 
an increase in HDL-C and antioxidant reserve in rabbits [145]. Penumathsa et al. [146] 
investigated the effects of SDG treatment on hypercholesterolemic rat hearts after 
ischemia/reperfusion injury. There was a significant reduction in total cholesterol, LDL-
cholesterol, triglycerides and an significant increase in HDL-cholesterol levels in SDG treated 
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rats as compared to the non-treated. Decreased infarct size, reduced ventricular remodeling and 
improvement in left ventricular functions was also observed in the SDG treated group. The 
angiogenic properties of SDG have been investigated in three different models. In an in vitro 
model, human coronary arteriolar endothelial cells treated with SDG showed a significant 
increase in tubular morphogenesis. In an ex vivo ischemia/reperfusion model, SDG-treated 
showed an increased level of aortic flow and functional recovery. Also, SDG reduced infarct size 
and decreased cardiomyocyte apoptosis. In an in vivo myocardial infarction model, SDG 
increased capillary density and myocardial function as evidenced by increased fractional 
shortening and ejection fraction [147]. Prasad [148] investigated the effect of Angiotensin I and 
treatment with SDG. SDG treatment produced reductions in systolic, diastolic, and mean arterial 
pressure [148]. In an H9c2 model of cardiac iron overload pretreatment with SDG reduced levels 
of ROS, expression of inflammatory cytokines and remodeling proteins and protein levels and 
activity of markers of apoptosis [149]. It is clear that SDG has protective antioxidant capabilities 
in many models of oxidative stress, but a possible role in PAH has not been investigated. 
 
 The objectives of this study were to examine the molecular mechanism(s) of MCT 
induced right heart failure and also, to determine if treatment with SDG can reduce damage 
caused by MCT induced oxidative stress. Based on previous work with this model, rats received 
a single MCT injection to induce PAH after 21 days. For the co-treatment group SDG treatment 
began on the day of MCT and continued for 21 days until the end of the study. We also 
pretreated a group of rats for 2 weeks prior to MCT injection and for 21 days after to see if 
pretreatment of SDG provided any additional benefical effects against PAH. Specifically, our 
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focus was to examine ROS and antioxidants to provide insight in the mechanism(s) of MCT 
induced cardiac damage and protection provided from SDG.  
 
Materials and Methods 
Animals 
 Five to six week old male Wistar rats were purchased from the Central Animal House at 
Universidade Federal do Rio Grande do Sul (UFRGS). Rats were housed in 270 x 260 x 310 mm 
cages with the floor covered in sawdust and with 4 rats per cage. During the treatment period 
animals were housed in the animal sector of the Pharmacology Department located in the 
Instituto de Ciências Básicas da Saúde (ICBS) at UFRGS. The housing room maintained at 22 ± 
2°C with a 12:12-h light:dark photoperiod. Rats were placed in 5 groups, 8 rats per group, 
identified as: 
1) Control 
2) SDG only  
3) MCT only 
4) SDG + MCT (co-treatment) 
5) SDG pre treatment + MCT 
Rats received a daily dose of 25 mg/kg of SDG (kindly provided by Dr Prasad from the 
University of Saskatchewan) via gavage or water for control groups for the duration of the study. 
Monocrotaline (Sigma-Aldrich) was given as a single intraperitoneal injection of 60 mg/kg 
(pH=7.4) at the beginning of SDG treatment. SDG pre treatment + MCT group followed the 
same protocol but instead SDG treatment began 2 weeks prior to monocrotaline treatment. After 
21 days rats were anesthetized with ketamine (90 mg/kg) and xylazine (10 mg/kg) and sacrificed 
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via decapitation. Blood was collected in heparinized tubes and centrifuged for 10 minutes at 
1000 x g. Separated plasma was collected and stored at -80°C.  
 
Tissue Weight Determination 
 Hearts were collected and total heart, right ventricle (RV) and left ventricle weights were 
measured. In order to obtain the wet/dry weight ratio of the lungs and livers the organs were 
freed from adhering tissues. Lungs and livers were weighed and placed in the oven at 40°C until 
a constant weight was observed. Collected tissues were stored at -80°C until further analysis.  
 
Hemodynamic Evaluation 
 Hemodynamic parameters were measured at the end of the treatment period just before 
animals were sacrificed. Rats were anesthetized with ketamine (90 mg/kg) and xylazine (10 
mg/kg) and catheterization of the right carotid artery was acheived with a PE 50 catheter 
connected to a transducer Strain Gauge (Narco Biosystem Pulse Transducer RP-155, Houston, 
TX) connected to a pressure amplifier (HP 8805C, Hewlett Packard, Palo Alto, CA). Pressure 
analysis was stored on a computer equipped with an analog-to-digital conversion board (Biopac 
1 kHz sampling frequency, Biopac Systems, Inc., Goleta, CA). Heart rate and ventricular systolic 
and ventricular diastolic pressure were recorded and analyzed using the Windaq software (Dataq 
Instruments, Inc., Akron, OH). 
  
Homogenization of tissue and total protein for enzymatic activity   
 A section of about 1/3 of each right ventricle was cut, weighed and placed in a separate 
eppendorf tube to be homogenated. Buffer composed of 1.15% KCl and 1% PMSF was added to 
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each section. Tissue was homogenized for 40 seconds then centrifuged for 20 minutes at 3000 
rpm. Supernatant was aliquoted and stored at -20°C. Protein concentration was measured via the 
Lowry method where bovine serum albumin was used to calculate protein concentration of 
samples read at 625 nm. 
 
Reactive oxygen species indicator assay 
 DCF-DA (2′, 7′ - dichlorofluorescein diacetate; Sigma-Aldrich) was used as an indicator 
of ROS. Homogenized samples were diluted in 1.15% KCl buffer. DCF-DA (Sigma-Aldrich) 
was added to each sample and then incubated for 30 minutes. Samples were added to a 96 well 
plate and read at 488 nm (Perkin Elmer LS 55 Fluorescence Spectrometer, Waltham, MA). A 
standard curve was calculated using different concentrations of DCF (0, 0.2, 1, 2 pmol/mg) and 
used to calculate the amount of ROS per mg of protein. 
 
Lipid peroxidation 
 To determine lipid peroxidation tert-butyl hydroperoxide–initiated chemiluminescence 
was measured in a liquid scintillation counter in the out-of-coincidence mode (LKB Rack Beta 
Liquid Scintillation Spectrometer 1215, LKB-Produkter AB, Sweden). Measurements were 
started by the addition of tert-butyl hydroperoxide to right ventricle homogenates. The reaction 
was allowed to initiate for 1 minute 30 seconds before being read. Each sample was read for 30 
seconds in triplicate until tert-butyl hydroperoxide reaction began to decrease. Data was 
expressed as counts per second (cps)/mg of protein. 
 
Antioxidant Enzyme Activity 
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   Catalase activity was calculated based on amount of H2O2 measured over 1 minute. In a 
cuvette 478 µL of 50mM potassium phosphate buffer, pH 7.4, was added followed by 5 µL of 
homogenated heart sample. The cuvette was then placed in the spectrophotometer. After 'zeroing' 
the absorbance 17.5 µL of H2O2 was added to the cuvette to start the reaction. Changes in 
absorbance was read at 240 nm (Cary 1E UV-Spectrophotometer, Agilent Technologies, Santa 
Clara, CA) for 1 minute where absorbance was recorded every 20 seconds. Absorbance was used 
to calculate nmol of catalase/mg of protein/ minute [150].  
  
 To calculate SOD activity homogenized hearts (1:10) were added to 50 mM Tris-HCl, pH 
8.2, containing 1 mM diethylenetriamine pentaacetic acid. SOD activity was determined by 
measuring the inhibition of pyrogallol (Sigma-Aldrich) autoxidation that is catalyzed by the 
superoxide radical. Pyrogallol (25 mM) was prepared in 10 mM HCl and stored at 4°C. Catalase 
(30 µM, prepared in an alkaline buffer, pH 9.0) was used to eliminate H2O2 from the reaction. 25 
µL of pyrogallol and 10 µL of catalase was added to samples in Tris Base (50 mM and 1 mM 
EDTA) and absorbance was measured at 420 nm (Agilent Technologies) for 2 minutes where 
absorbance was recorded at 0.5 and 1.5 minutes. Absorbance was used to calculate Units of 
SOD/mg of protein [151]. 
 
 GPx activity was determined by measuring the consumption of NADPH in the reduction 
reaction of GSSG to GSH. Heart homogenates (50 µL) was added to a cuvette containing 165 µL 
of 75 mM phosphate buffer, pH 7.0.  Then the following solutions were added: 250 µL of 
NADPH, 5 µL of sodium azide (143mM and 4mM EDTA), 25 µL of glutathione and 5 µL of 
glutathione reductase. The cuvette was then placed in the spectrophotometer. After 'zeroing' the 
74 
 
absorbance 25 µL of TBOOH (2 uL of tert-butyl hydroperoxide in 867 µL of H2O) to start the 
reaction and absorbance was measured at 340 nm (Agilent Technologies) for 2 minutes where 
absorbance was recorded at 0.5 and 1.5 minutes. Absorbance was used to calculate µmol activity 
of GPx/mg of protein [152]. 
 
Liver Toxicity Test - AST and ALT 
 Toxicity was measured via asparatate aminotransferase (AST) and alanine transaminase 
(ALT) tests. An increase in AST and ALT is indicative of liver toxicity. AST catalyzes the 
conversion of aspartate and ketoglutarate to oxaloacetate and glutamate. The AST/GOT 
Liquiform kit (Labtest, Lagoa Santa, MG, Brazil) was used to analyze AST levels. Plasma was 
diluted (1:10) in dH2O, added to Reagent 1 + 3 mixture and incubated for 5 minutes at 37°C. 
Reagent 2 was added and samples were read at 340 nm (T60 UV-Visible Spectrophotometer, PG 
Instruments, Leicestershire, UK) where absorbance was recorded at 1 minute and 2 minutes of 
reading. ALT catalyzes the conversion of alanine and ketoglutarate to pyruvate and glutamate. 
ALT was measured in a similar way but with the ALT/GPT Liquiform kit (Labtest). 
 
Statistics 
 Data were presented as mean ± standard error of the mean (SEM), and all data presented 
here represents n = 8 independent experiments. Statistical analyses were performed using 
GraphPad Prism software. One-way ANOVA with post hoc Tukey’s test were utilized when 
possible with p < 0.05 considered significant. Asterisks are used herein to denote significance 
according to the following scheme: * = p < 0.05; ** = p < 0.01; *** = p < 0.001; * = vs. control, 
# = vs. MCT, ^ = vs. MCT + SDG. 
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Results  
 
Weekly Weight Gain 
 Rats in control, SDG and SDG pre treatment + MCT had a similar average weekly weight 
gain between the groups (Figure 20). The weekly weight gain in MCT and SDG + MCT groups 
were similar to each other but slightly less than the average weekly weight gain of control, SDG 
and SDG pre treatment + MCT groups (Figure 20). 
 
Cardiac Hypertrophy and Liver and Lung Congestion 
 Cardiac hypertrophy was calculated by measuring heart or RV weight to total body 
weight. MCT treatment led to an increase in total heart/body weight and RV/body weight 
compared to control (Table 2), suggesting an increase in right ventricle hypertrophy. Co-
treatment of SDG with MCT also led to increased total heart/body weight and RV/body weight 
compared to control (Table 2), suggesting an increase in right ventricle hypertrophy. Heart/body 
weight and RV/body weight were near control levels in SDG pre-treatment group animals (Table 
2). Liver and lung congestion was calculated by measuring wet weight/dry weight. There was no 
change in lung wet weight/dry weight between any of the groups (Table 2). Liver wet weight/dry 
weight was increased in MCT + SDG animals compared to control (Table 2). 
 
Hemodynamics 
 Hemodynamic parameters were measured in the right ventricles of animals. RV systolic 
pressure (RVSP) was increased in MCT (P<0.001) and MCT + SDG (P<0.05) groups compared 
to control. RVSP was significantly less (P<0.001) in the SDG + MCT group compared to MCT 
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(Table 2). RV end diastolic pressure (RVEDP) was increased in the MCT (P<0.001) and MCT + 
SDG (P<0.05) groups compared to MCT. RVEDP was significantly less (P<0.05) in the SDG + 
MCT group compared to MCT and MCT + SDG groups (Table 2). dP/dt min and max was 
increased in MCT (P<0.01; P<0.05, respectively) compared to control (Table 2). 
 
Oxidative Stress 
 Oxidative stress was measured via DCF-DA (indicator of ROS levels) and 
chemiluminescence (indicator of lipid peroxidation). ROS levels did not change in MCT treated 
animals compared to control but did decrease in MCT + SDG and SDG + MCT groups 
compared to both control and MCT (Figure 21). Lipid peroxidation increased in MCT treated 
animals compared to control but was not significantly different in the  MCT + SDG group 
compared to control or MCT. Lipid peroxidation did decrease in the SDG + MCT group 
compared to MCT (Figure 22). 
  
Antioxidants 
 Enzymatic activity of antioxidants catalase, SOD and GPx was measured 
spectrophotometrically. Catalase (Figure 23), SOD (Figure 24) and GPx (Figure 25) activity did 
not change in MCT treated animals compared to control. Both catalase (Figure 23) and SOD 
(Figure 24) activity decreased in MCT + SDG and SDG + MCT groups compared to MCT. Only 
in the SDG + MCT group did GPx activity decrease compared to MCT (Figure 25). 
 
Liver Toxicity 
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 Plasma levels of ALT and AST (indicators of liver toxicity) were measured 
spectrophotometrically. ALT (Figure 26) and AST (Figure 27) levels were increased in MCT and 
MCT + SDG groups compared to control. SDG + MCT animals had decreased ALT and AST 
levels compared to MCT (Figure 26 & 27). 
 
Conclusion 
 
 PAH is known to lead to the development of right ventricular hypertrophy and heart 
failure. Our study has shown that treatment with SDG may offer some protection to the heart 
against oxidative stress in a model of PAH. Interestingly, pretreatment with SDG has shown to 
be a better treatment option rather than cotreatment.  
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
Tables 
 
Table 2. Morphometric and hemodynamic measurements of right ventricle 
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Figures 
 
Figure 20.  Average weekly body weight gain. All rats were weighed weekly during the study 
period. Graph represents the average weight of all eight rats per group.  
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Figure 21.  The effect of MCT and SDG on levels of reactive oxygen species in the right 
ventricle. ROS levels were assessed via DCF-DA. Bars represent mean ± SEM where n = 8 (*** 
= p < 0.001 versus control; ### = p < 0.001 versus MCT). 
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Figure 22.  The effect of MCT and SDG on lipid peroxidation in the right ventricle. Lipid 
peroxidation was assessed via chemiluminescence. Bars represent mean ± SEM where n = 8 (*= 
p < 0.05 versus control; # = p < 0.05 versus MCT). 
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Figure 23.  The effect of MCT and SDG on catalase activity in the right ventricle. 
Enzymatic activity of catalase was assessed via spectrophotometery. Bars represent mean ± SEM 
where n = 8 (# = p < 0.05 versus MCT). 
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Figure 24.  The effect of MCT and SDG on superoxide dismutase activity in the right 
ventricle. Enzymatic activity of SOD was assessed via spectrophotometery Bars represent mean 
± SEM where n = 8 (## = p < 0.01 versus MCT). 
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Figure 25.  The effect of MCT and SDG on glutathione peroxidase activity in the right 
ventricle. Enzymatic activity of GPx was assessed via spectrophotometery. Bars represent mean 
± SEM where n = 8 (** = p < 0.01 versus control). 
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Figure 26.  The effect of MCT and SDG on plasma alanine aminotransferase levels. Liver 
toxicity was assessed by measuring plasma levels of ALT. Bars represent mean ± SEM where n 
≥ 4 (* = p < 0.05 versus control; ## = p < 0.01 versus MCT). 
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Figure 27.  The effect of MCT and SDG on plasma aspartate aminotransferase levels. Liver 
toxicity was assessed by measuring plasma levels of AST. Bars represent mean ± SEM where n 
≥ 4 (* = p < 0.05 versus control; # = p < 0.05 versus MCT). 
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Chapter 5 - Discussion and Conclusion 
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Discussion 
  
 Oxidative stress has been implicated in many cardiovascular diseases including 
atherosclerosis and ischemia/reperfusion, ultimately leading to heart failure. Oxidative stress is 
the result of an imbalance of free radicals and enzymatic antioxidants. High levels of ROS can 
result in DNA, membrane and protein damage [17]. The majority of ROS is due to mitochondrial 
dysfunction, where O2•- leaks from the electron transport chain [20]. Leaked O2•- is readily 
converted to highly reactive •OH [21]. SOD catalyzes the dismutation of O2•- to H2O2 and O2 [21; 
43]. Catalase catalyzes the reduction of H2O2 to H2O in the cytoplasm [43]. GSH converts H2O2 
to H2O in the cytoplasm but requires GPx as a catalyst [43; 44]. During redox imbalance these 
enzymatic antioxidants are unable to handle the high levels of ROS and damage occurs. 
Therefore, non-enzymatic antioxidants may be a useful treatment for cardiovascular diseases due 
to oxidative stress. 
     
 Ionizing radiation can cause oxidative stress through the generation of ROS through 
radiolysis of water and mitochondrial dysfunction [26; 70]. This increase in ROS will damage 
DNA through base damage, base release, depolymerization, cross-linking, and strand breakage 
[63; 69]. Also, •OH generated by IR can induce peroxidation of mitochondrial inner membrane 
phospholipids, resulting in enhanced generation of O2•- from the mitochondria and persistent 
oxidative stress [70]. This generation of ROS can continue to arise [26] causing cellular damage 
long after initial exposure. A complex dietary supplement has previously been shown to prevent 
damage due to oxidative stress caused by radiation [88; 89]. Though the heart is particularly 
susceptible to radiation induced damage the use of antioxidants in radiation induced cardiac 
89 
 
damage has not been investigated. Therefore, for this thesis I investigated if the supplement can 
protect the heart from a whole body dose as well as a high dose to the head of ionizing radiation. 
 
 As shown in Chapter 2, when mice were given a 5 Gy whole body dose, radiation did 
seem to have an effect on protein levels of antioxidants and markers of apoptosis and autophagy 
at all three time points (48 hours, 30 days and 120 days). Catalase only changed at 120 after 
radiation, where protein levels increased. Mn-SOD was decreased at 48 hours and 30 days after 
radiation but was not different than control after 120 days. This likely due to the antioxidants 
response to the ROS present at each time point. Also, since mitochondria dysfunction is a 
common result of radiation exposure, this may lead to the decreased levels of Mn-SOD seen after 
48 hours and 30 days. Interestingly, both supplement treatment protocols led to an increase in 
catalase protein levels 48 hours after radiation. Catalase was also increased 120 days after 
radiation, but this may be due to the radiation rather than supplement as protein levels were 
similar to when exposed to radiation alone. Pre-treatment with the supplement may have had a 
positive effect in regards to Mn-SOD where protein levels were similar to control rather than 
radiation alone both after 48 hours and 30 days. Neither supplement treatment protocols had an 
effect on Mn-SOD 120 days after radiation, perhaps because at that time point radiation itself did 
not have an effect on Mn-SOD. In the future it would be interesting to see how other antioxidants 
are effected, such as glutathione and SOD1 and correlate it to levels of ROS. In regards to 
apoptosis, both treatment protocols has protective effects against radiation at most time points. 
Though, only when supplement was given after radiation were pro-caspase 3 levels decreased 
compared to radiation alone after 120 days. When measuring the Bax:Bcl2 ratio radiation and 
supplement had different affects on protein levels at different time points. What's interesting 
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though is it seems that protein levels of Bcl2 are affected rather than Bax. Perhaps Bcl2 is 
responding to the radiation rather than Bax levels increasing/decreasing. Lc3bII/I ratio was 
mainly affected after 120 days but since we only measured one marker of apoptosis we don't 
have enough information to definitively say that autophagy is induced by radiation or the 
supplement, or if autophagy is beneficial/detrimental. In the future it would be interesting to 
measure other autophagy markers, such as Atg5 and Beclin 1, to get a better picture of how 
autophagy is involved in radiation induced cardiac damage. Based on the information we have it 
does seem that the dietary supplement was beneficial to the heart in some cases.  
 
 In Chapter 3 mice were given a 10 Gy dose of radiation to the head and we investigated if 
the same supplement could protect against cardiac inflammation and fibrosis due to the abscopal 
effect. Radiation (and supplement) did not have an effect on inflammation or fibrosis in the 
mouse hearts. Since the abscopal effect to the heart from the brain has not been investigated we 
cannot say for certain if it does or does not exist. The reason we do not see an increase in 
inflammation or fibrosis after radiation may be because it is too soon to see a cardiac response. 
As stated in Chapter 2, patients treated with radiation as children and adolescents are more likely 
to suffer from cardiovascular complications, but not until later in life [83]. This is the same for 
patients who underwent radiation therapy for treatment of breast cancer [77]. Mortality from 
myocardial infarction was seen 40 years after radiation exposure from atomic bombs [76]. In our 
study, mice were sacrificed 30 days after radiation and, consequently, our model may not be 
appropriate to see cardiac damage caused by the abscopal effect. This may also explain why we 
did not see a strong negative effect on the heart after a WBD of 5 Gy in Chapter 2. Even 120 
days, our longest time point, may not be long enough to see full detrimental effects of radiation 
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to the heart in our mouse model. Future studies for both of these projects should use a life span 
study model to investigate radiation induced cardiac damage and if the dietary supplement can 
provide protection. 
 
 In Chapter 4 we used a different model of oxidative stress; monocrotaline treatment to 
induce PAH. PAH is known to lead to the development of right ventricular hypertrophy and 
heart failure [121]. Previously, most of the information on right heart failure was based on work 
with left heart failure. Farahmand et al [134] investigated antioxidant and oxidative stress 
changes using an i.p injection of MCT (60 mg/kg) to induce PAH subsequently leading to right 
heart failure. They found that 1 week after MCT injection right ventricle pressure overload and 
hypertrophy were increased. They also saw a slight increase in catalase, SOD and GPx activity. 2 
weeks after MCT injection there was a significant increase in catalase, SOD and GPx activity, an 
increase in septal wall thickness and compensated heart failure. 6 weeks after MCT injection 
they saw right ventrical dilation and failure, lung and liver congestion, decreased catalase, SOD 
and GPx activity, increased lipid peroxidation and severe bulging of the interventricular septum 
into the left ventricle. Based on these findings many studies have used a 3 week post MCT 
injection model to investigate possible treatment options in PAH before reaching the extent of 
right ventricular damage seen by Farahmand et al [134] at 6 weeks. Pretreatment with grape juice 
protected the right ventricle through decrease of oxidative stress and improvement of  
hemodynamic parameters 3 weeks after MCT injection [124; 133]. Studies on the effects of 
exercise training on MCT induced PAH, where male Wistar rats underwent exercise training for 
5 weeks pre MCT then 3 weeks post MCT injection, found that exercise training promoted 
positive changes in right ventricle and pulmonary artery remodeling and decreased H2O2 
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concentration and apoptotic signaling in the right ventricle [153; 154]. Based on previous 
positive results we chose to use a 3 week post MCT injection study period.  
 
 Treatment with SDG has been shown to protect against other cardiac models of oxidative 
stress, such as diabetes, atherosclerosis and iron overload. Therefore, we investigated if the same 
can be observed in our model of PAH. We saw vastly different results between pre-treated 
animals and co-treated.  Pre-treatment with SDG for two weeks provided much better protection  
against right ventricle damage caused by MCT compared to co-treatment. Right ventricle 
hypertrophy in the co-treatment group was similar to MCT alone while pre-treatment was similar 
to control and significantly less than MCT and co-treatment groups. Though, ROS levels and 
activity of catalase and SOD was significantly less in both pre- and co-treatment groups 
compared to MCT. These results led us to investigate plasma levels of markers of liver toxicity 
since both MCT and SDG are metabolized in the liver. ALT and AST were significantly higher 
in MCT and co-treated groups compared to control and pre-treated groups. Therefore, while we 
saw the antioxidant properties of SDG in the co-treatment group (reduced ROS and antioxidant 
activity) it was not enough to prevent the toxicity caused by MCT, which led to increased 
hypertrophy. In the future, it would be interesting to investigate markers of apoptosis and 
autophagy in this model. Also, further future directions of this study would be to see if treatment 
with SDG, particularly pretreatment with SDG, can still protect against MCT induced damage 4, 
5 and 6 weeks after injection, when right ventricle damage can be quite severe. 
 
 In Chapter 4 we saw that pre-treatment with an antioxidant was significantly better at 
providing protection against MCT, but there was not much difference between protection 
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provided by pre- and post-treatment against radiation seen in Chapter 2. This may be because in 
Chapter 4 only one antioxidant was used, while in Chapter 2 the supplement was composed of 
many. Or it could be because of the ROS itself. A major factor on the results seen in these 
studies seems to be the time point where ROS was measured. In Chapter 2 and 3 a high dose of 
radiation did not have as large of a negative effect as expected. This may be because it takes 
longer for ROS generation in the heart than the time points we measured at (in human studies 
oxidative stress is seen in the heart decades after radiation exposure). In Chapter 4 we did not see 
an increase in ROS as measured via DCF-DA but there was an increase in lipid peroxidation. It 
is likely that 21 days after MCT treatment is long enough to miss the increase of ROS but instead 
see the effects ROS (lipid peroxidation). Therefore, when it comes to treatment with antioxidants 
it is important to consider the extent of oxidative stress and level of ROS present at that time.  
 
 It is also important to consider the type of ROS present at a given time. ROS have 
important physiological functions, such as immune defense [17; 22] and inappropriate removal 
of ROS may cause paradoxical reductive stress and actually induce or promote disease [155]. 
Also, as mentioned earlier, different antioxidants, both enzymatic and non-enzymatic, will only 
react with certain ROS (for example, SOD catalyzes the dismutation of O2•- to H2O2 and O2 but 
does not react with •OH or H2O2). The complex dietary supplement used in Chapter 2 and 3 was 
designed to reduce •OH, O2•- and H2O2 at multiple cellular sites. Though previous studies have 
shown positive outcomes of using the supplement [86-88] in many clinical trials antioxidants 
have almost always failed to show a significant beneficial effects [155; 156]. Schmidt et al [155] 
state this may due to the fact that many studies showing beneficial effects of antioxidants in 
animals often do not monitor plasma concentrations of the supplemented antioxidant (which is 
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done in drug studies to determine safety and effectiveness). Therefore, they believe the possible 
lack of response to antioxidants in clinical studies is due to pharmacokinetic rather than 
pharmacodynamic reasons [155].  
 
 There are a number of limitations to this study. For Chapter 2 and 3 it would interesting 
to see if there were any hemodynamic changes due to the dose of radiation, but unfortunately the 
equipment was not available. In Chapter 2 pro-caspase 3 was used as an indicator of apoptosis 
via western blot. Though I tried increasing the amount of antibody and protein I could not 
visualize cleaved caspase 3, which would have given a better indication of apoptosis than pro-
caspase 3 alone. In Chapter 3 two stains were used, one for inflammation and one for fibrosis. 
Though both inflammation and fibrosis have been linked to oxidative stress the study would 
benefit from a stain specific for oxidative stress, such as 3 nitrotyrosine or 4 hydroxynonenal. 
Neither we nor the Laboratory Services Division of the Animal Health Laboratory of University 
of Guelph had the required stains or equipment. In Chapter 4 the enzymatic activity of 
glutathione peroxidase was measured but not glutathione, which together would give a better 
indication of antioxidant respone.  
 
 Further work needs to be done to determine the long term effects of radiation to the heart. 
A to-end-of-life study may offer interesting insight on radiation induced ROS in the heart and 
how antioxidants can be used for treatment. Also, further work is needed on the mechanism(s) of 
cardiovascular oxidative stress and antioxidant treatment. Though we looked at one marker of 
autophagy this is not enough do give us a definitive answer on how autophagy was affected in 
these studies. The role of autophagy may provide some insight into the cardiac response to 
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oxidative stress. Also, there exists a cross-talk between autophagy and apoptosis that has not 
been investigated in radiation or MCT induced oxidative stress in the heart. This would give us a 
better understanding of how the heart responds to oxidative stress and if and when treatment with 
antioxidants would be appropriate.  
 
Conclusion 
 
 Oxidative stress is known to be involved in many types of cardiovascular diseases. The 
work done in this thesis has shown that treatment with antioxidants may offer some protection to 
the heart in different models of oxidative stress. Pre-treatment appears to provide better 
protection against oxidative stress the co-treatment or post-treatment. Though, these studies 
provide a snapshot of the oxidative stress response at certain time points, and a study over a 
longer period of time may have different results. Therefore, it is important to consider the extent 
of oxidative stress and when ROS levels will be increased when developing a antioxidant 
treatment protocol.  
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